Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-kurarinone
non-competitive inhibitor
-
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
-
-
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
-
-
(2S)-2'-methoxy kurarinone
non-competitive inhibitor
-
(3-hydroxyphenyl)(phenyl)methanone
-
(3R,4S and 3S,4R)-3-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3,4-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
alpha-lapachone
(3S,4S and 3R,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzyloxy)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(benzylamino)-3,9-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(4E,4'E)-4,4'-bis(isopropylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(4E,4'E)-4,4'-bis(pentan-3-ylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
-
-
(E)-4-(isopropylimino)-2-methylnaphthalen-1(4H)-one
-
(R)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(1,4-dihydroxy-3-methylnaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
1,6,6-trimethyl-10,11-dioxo-2-(thiophen-3-yl)-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 29.3% inhibition
-
1,6,6-trimethyl-10,11-dioxo-2-phenyl-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 21.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl 1,3-thiazole-2-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl acetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl benzoate
0.02 mM, 54.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclohexanecarboxylate
0.02 mM, 48.0% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclopropanecarboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl furan-3-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl hydroxyacetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl thiophene-2-carboxylate
0.02 mM, 60.4% inhibition
-
1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 23.1% inhibition
1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 61.2% inhibition
-
1,6,6-trimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1,6,6-trimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 52.7% inhibition
-
1-(1,3-benzothiazol-2-ylsulfanyl)-N,N-dimethylmethanamine
-
1-(2-hydroxy-4-methylphenyl)-3-(2-methoxyphenyl)propane-1,3-dione
-
-
1-(2-hydroxy-4-methylphenyl)-3-{2-[(propan-2-yl)oxy]phenyl}propane-1,3-dione
-
-
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromothiophen-2-yl)-2-(3-methyl-1,4-dihydronaphthalen-2-yl)ethan-1-one
most potent inhibitor capable of blocking both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) activity, with the IC50 value for BT-549 cells at 0.00342 mM
-
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromophenyl)-2-[[5-(4-chlorophenyl)[1,3]thiazolo[2,3-c]-[1,2,4]triazol-3-yl]sulfanyl]ethanone
-
-
1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea
potent inhibitor. The basis for this high potency is a unique sulfur-aromatic interaction network formed by the thiourea moiety of the inhibitor with F163 and F226
-
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 68% inhibition
-
1-benzyl-5-phenyl-1H-imidazole
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
1-hydroxy-5,6-dimethoxy-3-oxo-2-phenyl-3H-indol-1-ium
-
1-methyl tryptophan
a tryptophan analogue. Galanal does not decrease the IkappaB-alpha expression in LPS-stimulated THP-1 cells
1-methyl-tryptophan
non-competitive inhibitor
1-oxo-2-phenyl-3H-1lambda5-indol-3-one
-
1-phenyl-2-(phenylsulfanyl)hydrazine
-
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
-
-
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-3-(4-methylphenyl)imidazolidin-2-one
-
-
1H-phenanthro[9,10-d]imidazole
-
2,2-dimethyl-1a,9b-dihydro-2H-benzo[g]oxireno[c]chromene-4,9-dione
-
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
dehydro-alpha-lapachone
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
2,2-dimethyl-3,4-epoxy-2H-naphtho[2,3-b]pyran-5,10-dione
-
2,3-dichloro-1,4-naphthoquinone
-
2-(1H-imidazol-4-yl)benzene-1,3-diol
-
2-(1H-imidazol-4-yl)benzenethiol
-
2-(1H-imidazol-4-yl)phenol
-
2-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
2-(1H-pyrazol-3-yl)phenol
-
2-(2-fluorophenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-methylphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(2-methylphenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzoic acid
0.1 mM, 8% inhibition
-
2-(4-methoxyphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(4-methoxyphenyl)-3H-indol-3-one
-
2-(4-methoxyphenyl)-3H-indole
-
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
-
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
poor inhibitor
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3,4-dihydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-cyanophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-hydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
-
2-amino-3-hydroxy-N-(4-hydroxynaphthalen-1-yl)propanamide
-
2-amino-N-(4-hydroxynaphth-1-yl)acetamide
-
2-bromo-4-phenyl-1,3-thiazole
0.1 mM, 12% inhibition
-
2-chloro-4-phenyl-1,3-thiazole
0.1 mM, 0.5% inhibition
-
2-chloro-N-[[(4-chlorophenyl)sulfanyl]methyl]aniline
-
2-Hydroxy-1,4-naphthoquinone
-
2-mercaptobenzothiazole
-
2-methoxy-1,4-naphthoquinone
-
2-methyl-1,4-naphthoquinone
-
2-methylnaphthalene-1,4-dione
-
2-phenyl-3H-indol-3-imine
-
2-phenyl-3H-indol-3-one
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
-
-
2-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
2-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-4(5H)-one
-
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
2-[[5-cyano-4-(3-methoxyphenyl)-6-oxo-1,6-dihydropyrimidin-2-yl]sulfanyl]-N-[5-(propan-2-yl)thiophen-2-yl]butanamide
0.01 mM, 24.4% inhibition
-
3'-[[(2-chlorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(2-fluorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(2-methylpropyl)(propan-2-yl)amino][1,1'-biphenyl]-2-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(4aS,8aS)-octahydroquinolin-1(2H)-yl][1,1'-biphenyl]-2-carboxylic acid
-
-
3-(1H-1,2,3-triazol-5-yl)pyridine
-
3-(1H-imidazol-4-yl)benzaldehyde
-
3-(1H-imidazol-4-yl)benzenethiol
-
3-(1H-imidazol-4-yl)benzonitrile
-
3-(1H-imidazol-4-yl)phenol
-
3-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
3-(2-aminoethyl)-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 74.88% inhibition
-
3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazole
-
-
3-(4H-imidazol-4-yl)benzenethiol
-
3-hydroxy-2,2-dimethyl-4-(morpholin-4-yl)-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
3-hydroxy-4-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
3-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
3-[2-(cyclohexylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.95% inhibition
-
3-[2-(diethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.21% inhibition
-
3-[2-(dimethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 71.26% inhibition
-
3-[2-(ethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 81.67% inhibition
-
3-[2-(propylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.17% inhibition
-
3-[2-(tert-butylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.45% inhibition
-
3-[2-[(2-phenylethyl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 68.26% inhibition
-
3-[2-[(propan-2-yl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 63.75% inhibition
-
3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoic acid
EC50 is 183 nm
4'-(2,3-dimethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-([[4-(2-hydroxypropan-2-yl)phenyl]carbamoyl]amino)-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-chlorophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-cyanophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methoxyphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-ethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylanilino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-2-fluoro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-ethoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-5-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(3-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(cyclohexylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(dibutylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[(2,3-dihydro-1H-inden-4-yl)oxy]-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-N-(methanesulfonyl)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxamide
-
-
4'-[bis(cyclopropylmethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclohexyl(methyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclopentyl(ethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4-(1H-1,2,3-triazol-5-yl)pyridine
-
4-(1H-imidazol-4-yl)phenol
-
4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
4-(2,6-dimethoxyphenyl)-1H-imidazole
-
4-(2-(diethylamino)ethylamino)-1-naphthol
-
4-(2-(methylthio)phenyl)-1H-imidazole
-
4-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 77% inhibition
-
4-(2-fluorophenyl)-1H-imidazole
-
4-(2-hydroxyethoxy)-1-naphthol
-
4-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 53% inhibition
-
4-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzonitrile
0.1 mM, 8% inhibition
-
4-(3-(methylthio)phenyl)-1H-imidazole
-
4-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 81% inhibition
-
4-(3-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 40% inhibition
-
4-(3-chlorophenyl)-imidazole
-
-
4-(3-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 28% inhibition
-
4-(3-fluorophenyl)-1H-imidazole
-
4-(4-(methylthio)phenyl)-1H-imidazole
-
4-(4-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 100% inhibition
-
4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 95% inhibition
-
4-(4-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 72% inhibition
-
4-(4-fluorophenyl)-1H-imidazole
-
4-(4-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 68% inhibition
-
4-(4-methylbenzene-1-sulfinyl)-7-nitro-2,1,3-benzoxadiazole
-
4-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 90% inhibition
-
4-(benzylamino)-1-naphthol
-
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(cyclohexylamino)-1-naphthol
-
4-(dimethylamino)naphthalen-1-ol
-
4-(ethylamino)-1-naphthol
-
4-(isobutylamino)-1-naphthol
-
4-(isopropylamino)-1-naphthol
-
4-(methanesulfonyl)-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC5 is 7846 nm
4-(methylamino)naphthalen-1-ol
-
4-(pent-3-ylamino)-1-naphthol
-
4-(propylamino)-1-naphthol
-
4-(pyridin-3-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
4-(pyridin-4-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 21% inhibition
-
4-(tert-butylamino)naphthalen-1-ol
-
4-(thiophen-2-yl)-1H-imidazole
-
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
-
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
4-bromo-N'-(4-bromophenyl)benzene-1-sulfonohydrazide
EC50 is 374 nm
4-chloro-2-(1H-1,2,3-triazol-4-yl)phenol
i.e. MMG-0358
-
4-chlorophenyl-1,2,3-triazol-4-amine
-
-
4-cyano-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC50 is 3404 nm
4-fluoro-2-(1H-pyrazol-3-yl)phenol
-
4-methoxy-1-naphthylamine
-
4-methoxy-3'-[(phenylcarbamoyl)amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(2-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(3-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-(2-propylphenoxy)[1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-methyl-3-[(prop-2-yn-1-yl)oxy]phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-nitro-2,1,3-benzothiadiazole
-
4-nitro-7-[(1-oxo-1lambda5--pyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole
-
4-phenyl-1,3-thiazol-2(3H)-one
0.1 mM, 15% inhibition
-
4-phenyl-1,3-thiazol-2-amine
4-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 76% inhibition
-
4-phenyl-1,3-thiazole-2-thiol
-
4-phenyl-imidazole
4-phenyl-imidazole coordinates transiently to the heme iron
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
-
-
4-[(2,4-dichlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(3-chlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
4-[(4-fluorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4-methylphenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzamide
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
4-[2-(4-bromophenyl)hydrazinesulfonyl]benzoic acid
EC50 is 172 nm
4-[2-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[3-(hydroxymethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
4-[3-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[4-(trifluoromethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 37% inhibition
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-2(1H)-one
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]pyrimidin-2(1H)-one
-
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
-
-
5-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 29% inhibition
-
5-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 12% inhibition
-
5-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
5-(4-chlorophenyl)-3-[(2-methylpropyl)sulfanyl][1,3]thiazolo-[2,3-c][1,2,4]triazole
-
-
5-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 15% inhibition
-
5-(ethylamino)quinolin-8-ol
-
5-(isopropylamino)quinolin-8-ol
-
5-amino-8-hydroxyquinoline
-
5-chloro-1,3-benzothiazole-2(3H)-thione
-
5-hydroxy-1,4-naphthoquinone
-
5-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
5-phenyl-1H-1,2,3-triazole
-
5-[(2E)-2-[(4-bromophenyl)methylidene]hydrazinyl]-1-(naphthalen-1-yl)tetrazolidine
0.01 mM, 54.3% inhibition
-
5-[[(2,4-dichlorophenyl)methyl]sulfanyl]-1H-1,2,4-triazole
-
6-(4-iodo-2-methylanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
6-(4-iodo-2-methylanilino)-3-oxo-2,1,3lambda~5~-benzoxadiazole-5-carboxylic acid
-
6-bromo-1H-indazol-4-amine
-
-
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
-
-
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
-
-
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2R)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-amino-2-[(2E)-3-(2H-1,3-benzodioxol-5-yl)prop-2-enoyl]-4-bromocyclohepta-2,4,6-trien-1-one
0.01 mM, 21.4% inhibition
-
7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
-
-
7-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-nitro-N-phenyl-2,1,3-benzoxadiazol-4-amine
-
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
-
-
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
8-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
9-hydroxy-1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
-
-
9-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
alpha-caryopterone
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
antisense oligonucleotide A06007H
+G*+A*+T*T*G*T*C*C*A*G*G*A*+G*+T*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06008H
+C*+T*+C*A*A*C*T*C*T*T*T*C*+T*+C*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06030H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*+T*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06043H
+C*+C*+A*G*A*C*T*C*T*A*T*G*A*G*+A*+T*+C, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06044H
+G*+A*+G*A*T*G*A*T*C*A*A*T*G*C*+T*+G*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06045H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*T*+G*+T*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07006H
+T*+G*+T*A*T*G*A*C*A*G*C*+C*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07058H
+A*+T*+C*G*T*G*G*T*G*C*T*G*A*A*+C*+A*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
-
-
ethyl 1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl (2E)-but-2-enedioate
-
-
galanal
competitive inhibitor, IC50 value of 45 nM in the cell-based assay. galanal interfered with the transcriptional function of the nuclear factor-kappaB and the interferon-gamma signaling pathway. These effects of galanal are important for immune response. The inhibitory effect of galanal on IDO1 activity is stronger than that of 1-methyl tryptophan, a tryptophan analogue
gamma-glutamyl-S-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cysteinylglycine
-
INCB024360
0.01 mM, 97.59% inhibition
-
kushenol E
non-competitive inhibitor, the inhibitor might be useful in the development of immunotherapeutic agents against cancers
kushenol F
non-competitive inhibitor
-
menadione
menadione effectively inhibits L-Trp oxidation from reactions supported with ascorbaic acid/methylene blue
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
-
-
methyl 2-methyl-5,10-dioxo-5,10-dihydro-2H-benzo[g]chromene-2-carboxylate
-
methyl 3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoate
EC50 is 465 nm
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
-
-
methyl 7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylate
-
methyl thiohydantoin-Trp
-
methylene blue
addition of methylene blue (0-0.1 mM) to NADPH-cytochrome P450 reductase-supported D-Trp incubations (with or without cytochrome b5) leads to concentration-dependent inhibition of IDO activity, addition of methylene blue (0-0.03 mM) to NADPH-cytochrome P450 reductase-supported L-Trp oxidation reactions results in a switch from substrate inhibition kinetics to Michaelis-Menten with increasing methylene blue concentration decreasing the affinity of IDO for L-Trp
N'-(3-methylphenyl)-4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzene-1-sulfonohydrazide
EC50 is 296 nm
N'-(4-bromophenyl)-4-cyanobenzene-1-sulfonohydrazide
EC50 is 134 nm
N'-(4-bromophenyl)-4-methoxybenzene-1-sulfonohydrazide
EC50 is 640 nm
N'-(4-bromophenyl)benzenesulfonohydrazide
EC50 is 128 nm
N'-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N-methyl-N-(4-methylphenyl)urea
-
-
N,N-dimethyl-1-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]methanamine
-
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
-
-
N-(4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-yl)-1,1,1-trifluoromethanesulfonamide
-
-
N-(4-bromophenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-bromophenyl)-N'-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]urea
-
-
N-(4-chlorophenyl)-2H-1,2,3-triazol-4-amine
i.e. Vertex-AT
-
N-(4-hydroxy-1-naphthyl)ethane-1,2-diaminium chloride
-
N-(4-hydroxy-1-naphthyl)propane-1,3-diaminium chloride
-
N-(4-hydroxynaphthalen-1-yl)pyrrolidine-2-carboxamide
-
N-(4-methoxyphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-[2-[4-(trifluoromethyl)phenyl]hydrazinesulfonyl]phenyl)acetamide
EC50 is 181 nm
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
-
-
N-(phenyldisulfanyl)aniline
-
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
poor inhibitor
N-phenyl-p-phenylenediamine
-
N-[(1,3-benzothiazol-2-yl)sulfanyl]-2-nitrobenzene-1-sulfonamide
0.01 mM, 35.9% inhibition
-
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[(E)-(2-phenyl-3H-indol-3-yl)methylidene]hydroxylamine
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-3-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-4-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-(4-cyanophenyl)acetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methyl-4-nitrobenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methylacetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-phenylacetamide
-
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]-2,2-dimethylpropanamide
0.01 mM, 72.35% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]acetamide
0.01 mM, 57.47% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzamide
0.01 mM, 65.72% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzenesulfonamide
0.01 mM, 59.71% inhibition
-
N-[4-(2-phenylhydrazinesulfonyl)phenyl]acetamide
EC50 is over 0.010 mM
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(2-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(3-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-phenylurea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(difluoromethoxy)phenyl]urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(trifluoromethoxy)phenyl]urea
-
-
N-[4-[2-(2,4-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3,4-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 350 nm
N-[4-[2-(3,5-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 508 nm
N-[4-[2-(3,5-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2229 nm
N-[4-[2-(3-bromo-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2494 nm
N-[4-[2-(3-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 7563 nm
N-[4-[2-(3-chloro-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2588 nm
N-[4-[2-(3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]benzoyl]glycine
EC50 is 571 nm
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 241 nm
N-[4-[2-(4-bromo-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 187 nm
N-[4-[2-(4-bromo-3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 130 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-cyanophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-fluorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-butylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-cyclohexylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[3-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[4-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 85 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]butanamide
EC50 is 187 nm
N-[4-[2-(4-chloro-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 84 nm
N-[4-[2-(4-chlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 142 nm
N-[4-[2-(4-cyanophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1393 nm
N-[4-[2-(4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 609 nm
N-[4-[2-(4-methoxyphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(4-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1171 nm
N-[4-[2-(4-sulfamoylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 3118 nm
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
-
-
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-2-nitroaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-methylaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-nitroaniline
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-2-hydroxyacetamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-4-oxobutanamide
0.001 mM, 97% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-(phenylacetyl)glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(2-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3,4-dihydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-cyanophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N2-[(2S)-2-amino-2-phenylacetyl]-N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]glycinamide
-
-
NO
can inhibit hIDO by directly binding to the heme iron
noranhydroicaritin
non-competitive inhibitor
norharmane
NHM, noncompetitive versus L-Trp and competitive versus O2
propan-2-yl 4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoate
-
-
S-(2-chlorophenyl) (4-chlorophenyl)carbamothioate
-
sophoraflavanone B
non-competitive inhibitor
streptovaricin C
NSC19990
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
-
-
tert-butyl [2-(4,7-dioxo-5-phenyl-4,7-dihydro-1H-indol-3-yl)ethyl]carbamate
0.01 mM, 56.38% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 66.51% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-4-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 12.42% inhibition
-
tert-butyl [2-[5-(2-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 67.30% inhibition
-
tert-butyl [2-[5-(2-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 63.23% inhibition
-
tert-butyl [2-[5-(4-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 43.34% inhibition
-
tert-butyl [2-[5-(4-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 34.45% inhibition
-
tert-butyl [2-[5-(4-methylphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 25.52% inhibition
-
[3-(4-bromobenzoyl)-1,2-oxazol-4-yl](naphthalen-2-yl)methanone
0.01 mM, 28.4% inhibition
-
[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenoxy]acetic acid
EC50 is 152 nm
(10Z,13Z)-nonadecadienoic acid
-
32% inhibition at 0.02 mM
(11Z,14Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(11Z,14Z,17Z)-eisosatrienoic acid
-
19% inhibition at 0.02 mM
(12Z,15Z)-heneicosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z)-docosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z,19Z)-docosatrienoic acid
-
52% inhibition at 0.02 mM
(2,4-dichlorophenyl)methanethiol
-
-
(2-chlorophenyl)methanethiol
-
-
(3,4-dichlorophenyl)methanethiol
-
-
(4-chlorophenyl)methanethiol
-
-
(4-chlorophenyl)methanol
-
-
(4-fluorophenyl)methanethiol
-
-
(4-methoxyphenyl)methanethiol
-
-
(4-methylphenyl)methanethiol
-
-
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid
-
48% inhibition at 0.02 mM
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
-
35% inhibition at 0.02 mM
(5Z,8Z)-7,7-dimethyl-5,8-eicosadienoic acid
-
29% inhibition at 0.02 mM
(5Z,8Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(5Z,8Z,11Z)-eisosatrienoic acid
-
45% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
-
19% inhibition at 0.02 mM
(7Z,10Z,13Z,16Z)-docosatetraenoic acid
-
42% inhibition at 0.02 mM
(8Z,11Z,14Z)-eisosatrienoic acid
-
68% inhibition at 0.02 mM
(9E,11Z)-octadecadienoic acid
-
26% inhibition at 0.02 mM
(9E,12E)-octadecadienoic acid
-
23% inhibition at 0.02 mM
(9Z,12Z)-octadecadienoic acid
-
16% inhibition at 0.02 mM
(9Z,12Z,15Z)-octadecatrienoic acid
-
23% inhibition at 0.02 mM
1-(4-chlorobenzyl)urea
-
-
1-(4-chlorophenyl)methanamine
-
-
1-(4-chlorophenyl)thiourea
-
-
1-benzofuran-DL-tryptophan
-
1 mM, 43% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-benzothiophene-DL-tryptophan
-
1 mM, 16% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-[2-(4-chlorophenyl)ethyl]thiourea
-
-
15-deoxy-DELTA12,14-prostaglandin
-
-
2,4-dichlorobenzyl carbamimidothioate hydrobromide
-
-
2-(1H-imidazol-4-yl)phenol
-
-
2-(2-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(3-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(4-chlorophenyl)ethanamine
-
-
2-(4-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
poor inhibitor
2-bromo-L-tryptophan
-
1 mM, 11% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chloro-L-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chlorobenzyl carbamimidothioate hydrochloride
-
-
2-hydroxy-L-tryptophan
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
3,4-dichlorobenzyl carbamimidothioate hydrochloride
-
-
3-(1H-1,2,3-triazol-5-yl)pyridine
-
-
3-chlorobenzyl carbamimidothioate hydrochloride
-
-
4-(phenylcarbonyl)benzyl carbamimidothioate hydrobromide
-
-
4-(propan-2-yl)benzyl carbamimidothioate hydrobromide
-
-
4-(trifluoromethyl)benzyl carbamimidothioate hydrochloride
-
-
4-amino-1,2,3-oxadiazole-3-carboximidamide
-
-
4-amino-1,2,5-oxadiazole-3-carboximidamide
-
competitive
4-amino-N'-hydroxy-N-(3-isopropylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methoxyphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(2-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chlorophenyl)-1,2,5-oxadiazole-3-carbohydrazonamide
-
-
4-amino-N-(3-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-ethylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-tert-butylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(4-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-benzyl-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-bromo-5-(4-methylphenyl)-1H-1,2,3-triazole
-
-
4-bromobenzyl carbamimidothioate hydrobromide
-
-
4-chlorobenzenesulfonic acid
-
-
4-chlorobenzyl carbamimidothioate hydrochloride
-
-
4-chlorobenzyl N,N'-dimethylcarbamimidothioate - 1-chlorotetraoxidane (1:1)
-
-
4-cyanobenzyl carbamimidothioate hydrobromide
-
-
4-ethylbenzyl carbamimidothioate hydrochloride
-
-
4-fluorobenzyl carbamimidothioate hydrochloride
-
-
4-iodo-5-phenyl-1H-1,2,3-triazole
-
-
4-methoxybenzyl carbamimidothioate hydrochloride
-
-
4-methyl-DL-tryptophan
-
1 mM, 26% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
4-methylbenzyl carbamimidothioate hydrochloride
-
-
4-nitro-5-(4-nitrophenyl)-1H-1,2,3-triazole
-
-
4-nitrobenzyl carbamimidothioate hydrochloride
-
-
4-tert-butylbenzyl carbamimidothioate hydrobromide
-
-
4-[(carbamimidoylsulfanyl)methyl]benzoic acid hydrochloride
-
-
5-(2-bromophenyl)-1H-1,2,3-triazole
-
-
5-(2-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(2-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-(4-bromophenyl)-1H-1,2,3-triazole
-
-
5-(4-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(4-fluorophenyl)-1H-1,2,3-triazole
-
-
5-(4-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-benzyloxy-DL-tryptophan
-
1 mM, 2% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-bromo-DL-tryptophan
-
1 mM, 56% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-fluoro-DL-tryptophan
-
1 mM, 32% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-hydroxy-L-tryptophan
-
1 mM, 12% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-methoxy-DL-tryptophan
-
1 mM, 35% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-methyl-DL-tryptophan
-
1 mM, 6% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-phenyl-1H-1,2,3-triazole
-
-
6-fluoro-DL-tryptophan
-
1 mM, 54% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-methyl-DL-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-D-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-L-tryptophan
-
1 mM, competitive inhibition, 52% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
7-methyl-DL-tryptophan
-
1 mM, 36% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
alpha-methyl-DL-tryptophan
-
1 mM, 1% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
alpha-N-methyl-L-tryptophan
-
1 mM, 33% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
baicalein
-
uncompetitive reversible potent IDO-1 inhibitor
benzyl carbamimidothioate hydrochloride
-
-
Berberine
-
uncompetitive reversible potent IDO-1 inhibitor
beta-Methyl-DL-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
D-tryptophan
low inhibition
epigallocatechin gallate
-
-
ethyl 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate
-
-
imidodicarbonimidic diamide, N-methyl-N''-9-phenanthrenyl-, monohydrochloride
-
-
Indole-3-propionic acid
-
-
Jatrorrhizine
-
irreversible potent IDO-1 inhibitor
L-tryptophan ethyl ester
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
L-tryptophan methyl ester
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
methyl 4-[(carbamimidoylsulfanyl)methyl]benzenesulfinate hydrobromide
-
-
methyl N-(4-chlorophenyl)carbamimidothioate hydroiodide
-
-
methyl N-[2-(4-chlorophenyl)ethyl]carbamimidothioate hydroiodide
-
-
methyl thiohydantoin-Trp
-
methyl-thiohydantoin tryptophan
-
-
methyl-thiohydantoin-L-tryptophan
-
competitive inhibitor
methyl-thiohydantoin-tryptophan
-
limited selectivity towards indoleamine 2,3-dioxygenase
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2
N-acetyl-L-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
poor inhibitor
N1-acetyl-N2-formyl-5-methoxykynurenine
-
NSC 401366
-
competitive with respect to tryptophan
palmatine
-
irreversible potent IDO-1 inhibitor
prostaglandin (19R)-hydroxy-PGE2
-
-
prostaglandin 13,14-dihydro-15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGF2alpha
-
-
prostaglandin 20-hydroxy PGE2
-
-
prostaglandin DELTA12-PGJ2
-
-
prostaglandin PGD2 ethanolamide
-
-
prostaglandin PGE2 ethanolamide
-
-
prostaglandin PGF2beta
-
-
sodium 4-chlorobenzenesulfinate
-
-
transforming growth factor-beta
-
inhibits expression in skin and synovial fibroblasts
-
[4-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[4-(1-oxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[5-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[5-(1-oxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
-
-
1-methyl-L-tryptophan
-
1-methyl-L-tryptophan
-
-
1-methyl-L-tryptophan
competitive inhibition of IDO1, antitumour activity, selectivity of 1-methyl L-tryptophan inhibition of IDO1 and IDO2
1-methyl-L-tryptophan
competitive versus L-Trp and noncompetitive versus O2. When 1-Me-L-Trp is the only indoleamine in the reaction mixture, it is a very slow substrate for hIDO1
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
0.001 mM, 73% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
0.001 mM, 69% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
0.001 mM, 89% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
0.001 mM, 72% inhibition
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
i.e. Incyte-5l
4-phenyl-1,3-thiazol-2-amine
-
4-phenyl-1,3-thiazol-2-amine
0.1 mM, 13% inhibition
4-phenylimidazole
-
4-phenylimidazole
weak noncompetitive inhibitor of IDO
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
potent inhibitor with a moderate pharmacokinetic profile. 25% tumor growth inhibition and 30% reduction in tumor weight in a murine CT26 syngeneic model on day 18, with 100 mg/kg oral administration twice daily
-
epacadostat
-
-
epacadostat
pH and temperature not specified in the publication
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
0.001 mM, 62% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
0.001 mM, 67% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
0.001 mM, 65% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
0.001 mM, 66% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
0.001 mM, 63% inhibition
-
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid
-
55% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid
-
80% inhibition at 0.02 mM
1-methyl-D-tryptophan
-
-
1-methyl-D-tryptophan
-
competitive inhibitor
1-methyl-D-tryptophan
-
IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
1-methyl-D-tryptophan
-
the isomer is more effective in inhibiting IDO than 1-methyl-L-tryptophan
1-methyl-D-tryptophan
-
selective inhibition of IDO2, 1DMT is not efficacious in a tumor model on an IDO1-/- background
1-methyl-D-tryptophan
competitive inhibition of IDO2, antitumour activity, selectivity of 1-methyltryptophan inhibition of IDO1 and IDO2
1-methyl-DL-Trp
-
-
1-methyl-DL-tryptophan
-
-
1-methyl-DL-tryptophan
-
1 mM, 26% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-methyl-DL-tryptophan
-
competitive inhibition with L-tryptophan, 2 mM, 70% inhibition
1-methyl-L-tryptophan
-
-
1-methyl-L-tryptophan
-
competitive inhibitor
1-methyl-L-tryptophan
-
substrate inhibition, 1-methyl-D-tryptophan exhibits no inhibitory effect
1-methyl-L-tryptophan
-
the isomer is less effective in inhibiting IDO than 1-methyl-D-tryptophan
1-methyl-L-tryptophan
-
better inhibitor of IDO2 enzymatic activity than 1DMT in both cell-free and cellular assays
1-methyl-L-tryptophan
competitive inhibition of IDO2, antitumour activity, selectivity of 1-methyltryptophan inhibition of IDO1 and IDO2
1-methyl-tryptophan
-
-
1-methyl-tryptophan
-
competitive
1-Methyltryptophan
-
-
1-Methyltryptophan
-
competitive
1-Methyltryptophan
-
2 mM, 70% inhibition
cyanide
-
prebinding of cyanide to the enzyme facilitates L-Trp binding by 22fold but retards its dissociation by 2fold, indicating that cyanide binding to the heme iron introduces structural changes to the protein matrix allowing faster access of the substrate to the active site and slower dissociation from it. Prebinding of L-Trp to the enzyme retards cyanide binding by about 13fold
cyanide
-
inhibits the dioxygenase activity
exiguamine A
-
-
exiguamine A
-
inihibor isolated from the marine sponge Neopetrosia exigua
H2O2
-
-
H2O2
at high concentrations
H2O2
-
inhibits the dioxygenase activity in a manner abrogated by L-Trp. Physiological peroxidase substrates, ascorbate or tyrosine, enhanced rIDO-mediated H2O2 consumption and attenuated H2O2-induced protein oxidation and dioxygenase inhibition. H2O2 alters the heme active site of recombinant IDO
L-tryptophan
-
substrate inhibition
L-tryptophan
-
substrate inhibition at 0.14 mM and greater
L-tryptophan
-
substrate inhibition (above 0.05 mM)
NO
-
-
NO
-
inhibits activity reversibly by binding to the active site heme to trap the enzyme as an inactive nitrosyl-FeII enzyme adduct with Trp bound and O2 displaced. Reversible inhibition by NO may represent an important mechanism in controlling the immune regulatory actions of IDO
norharman
-
2 mM, 98% inhibition, uncompetitive
norharman
-
uncompetitive inhibition, 2 mM, 98% inhibition
tryptamine
-
-
additional information
review article sumarizing data of many inhibitors of indoleamine 2,3-dioxygenase
-
additional information
not inhibited by 1-methyl-D-tryptophan
-
additional information
F5H5G0
no inhibition by phenylthiohydantoin-Trp
-
additional information
no inhibition by phenylthiohydantoin-Trp
-
additional information
-
no inhibition by phenylthiohydantoin-Trp
-
additional information
identification of substituted naphthotriazolediones as tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening, homology modeling and virtual screening, ligand docking analysis, overview
-
additional information
NCI library inhibitor screening, and analysis of active site-inhibitor interactions, overview. Importance of Ser167 and Cys129 residues in the IDO1 active site for inhibitor binding. Structure-activity relationship studies propose substituents interacting with Ser167 on four investigated IDO1 inhibitors. Three of these four Ser167 interactions associate with an increased IDO1 inhibition and are correctly predicted by molecular docking supporting Ser167 as an important mediator of potency for IDO1 inhibitors. IC50 values in presence or absence of Tween 20 and reduced glutathione
-
additional information
no inhibition of IDO1 by 1-methy-D-tryptophan
-
additional information
no inhibition of IDO1 by 1-methy-D-tryptophan
-
additional information
-
no inhibition of IDO1 by 1-methy-D-tryptophan
-
additional information
structure-activity relationships of phenyl benzenesulfonylhydrazides as indoleamine 2,3-dioxygenase inhibitors, overview. Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides are utilized to synthesize the sulfonylhydrazides bearing various substituents. EC50 values, overview
-
additional information
suppressive effect of plant extracts or phytochemicals on IDO1 induction and activity. The methanol extracts of Myoga flower buds, which are traditional Japanese foods, and labdane-type diterpene galanal derived from Myoga flowers significantly suppress IDO1 activity
-
additional information
-
suppressive effect of plant extracts or phytochemicals on IDO1 induction and activity. The methanol extracts of Myoga flower buds, which are traditional Japanese foods, and labdane-type diterpene galanal derived from Myoga flowers significantly suppress IDO1 activity
-
additional information
1H-indazole-4-amines inhibit both human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) by a mechanism involving direct coordination with the heme ferrous and ferric states
-
additional information
-
1H-indazole-4-amines inhibit both human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) by a mechanism involving direct coordination with the heme ferrous and ferric states
-
additional information
a high throughput virtual screening cascade protocol is validated and can be employed in discovery of IDO1 inhibitors
-
additional information
-
not inhibited by 6-nitro-D-tryptophan and indole-nitrogen substituted analogues of trytophan
-
additional information
-
not inhibited by indo-3-acetamide, beta-indoylacetonitrile snd 3-beta-indoleacrylic acid
-
additional information
-
sodium butyrate does not inhibit the activity of IDO
-
additional information
-
the traditional Chinese medicinal prescription Oren-gedoku-to significantly inhibits recombinant human IDO-1 activity in vitro
-
additional information
F5H5G0
no inhibition by phenylthiohydantoin-Trp
-
additional information
no inhibition by phenylthiohydantoin-Trp
-
additional information
-
no inhibition by phenylthiohydantoin-Trp
-
additional information
-
structure-activity relationship and enzyme kinetics of 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase inhibitors, molecular docking studies, overview. An electron-withdrawing group with low steric hindrance near the NH group of triazoles is necessary for the IDO inhibition. No inhibition by 5-(4-methylphenyl)-1H-1,2,3-triazole, methyl 4-(1H-1,2,3-triazol-5-yl)benzoate, 4-bromo-5-phenyl-1H-1,2,3-triazole, 4-chloro-5-phenyl-1H-1,2,3-triazole, 1H-benzotriazol-1-ol, and 5-(4-bromophenyl)-1H-tetrazole
-
additional information
-
the dioxygenase enzyme activity is inhibited by free radical scavengers. Protection of the dioxygenase enzyme function by L-Trp coincides with its oxidation into oxindolylalanine and kynurenine and the formation of a compound II-type ferryl-oxo heme
-
additional information
-
inhibition of indoleamine 2,3-dioxygenase activity by fatty acids, eicosanoids and prostaglandins, structure-function-analysis, overview. No inhibition by (6Z,9Z,12Z)-octadecatrienoic and (6Z,9Z,12Z,15Z)-octadecatetraenoic
-
additional information
no inhibition of IDO1 by L-tryptophan
-
additional information
no inhibition of IDO1 by L-tryptophan
-
additional information
-
no inhibition of IDO1 by L-tryptophan
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Role of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase in Patients with Recurrent Miscarriage.
Abortion, Spontaneous
Coding region polymorphisms in the indoleamine 2,3-dioxygenase (INDO) gene and recurrent spontaneous abortion.
Abortion, Spontaneous
Indoleamine 2,3-dioxygenase levels at the normal and recurrent spontaneous abortion fetal-maternal interface.
Acquired Immunodeficiency Syndrome
HIV-1 Tat Protein Induces the Production of IDO in Human Monocyte Derived-Dendritic Cells through a Direct Mechanism: Effect on T Cells Proliferation.
Acquired Immunodeficiency Syndrome
Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: A possible mechanism for AIDS comorbid depression.
Acquired Immunodeficiency Syndrome
Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling.
Acquired Immunodeficiency Syndrome
Tryptophan depletion in context of the inflammatory and general nutritional status of a low-income South African HIV-infected population.
Acute Coronary Syndrome
Indoleamine 2,3-Dioxygenase (IDO) Enzyme Links Innate Immunity and Altered T-Cell Differentiation in Non-ST Segment Elevation Acute Coronary Syndrome.
Acute Kidney Injury
Indoleamine-2,3-Dioxygenase Activates Wnt/?-Catenin Inducing Kidney Fibrosis after Acute Kidney Injury.
Adenocarcinoma
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Adenocarcinoma
Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Adenocarcinoma
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Adenocarcinoma
Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.
Adenocarcinoma
Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on ?? T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells.
Adenocarcinoma of Lung
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Adenocarcinoma of Lung
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Adrenocortical Carcinoma
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Alopecia
Fibroblast cell-based therapy prevents induction of alopecia areata in an experimental model.
Alopecia Areata
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Alzheimer Disease
Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease.
Alzheimer Disease
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus.
Alzheimer Disease
Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease.
Alzheimer Disease
Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease.
Alzheimer Disease
Swimming exercise prevents behavioural disturbances induced by an intracerebroventricular injection of amyloid-?1-42 peptide through modulation of cytokine/NF-kappaB pathway and indoleamine-2,3-dioxygenase in mouse brain.
Alzheimer Disease
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Alzheimer Disease
The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease.
Anemia
Proceedings: Rat liver tryptophan pyrrolase activity in iron deficiency anaemia.
Anemia, Aplastic
[An experimental study on the regulation of bone marrow-derived mesenchymal stem cells through indoleamine 2,3-dioxygenase signaling pathway by thymosin ?1 for improving the immunosuppression mediated by T cell].
Anemia, Hemolytic, Autoimmune
Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia.
Anemia, Iron-Deficiency
Proceedings: Rat liver tryptophan pyrrolase activity in iron deficiency anaemia.
Anhedonia
Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge.
Anhedonia
Major depression model induced by repeated and intermittent lipopolysaccharide administration: Long-lasting behavioral, neuroimmune and neuroprogressive alterations.
Anhedonia
Mapping inflammation onto mood: Inflammatory mediators of anhedonia.
Arrhythmias, Cardiac
Circadian arrhythmia dysregulates emotional behaviors in aged Siberian hamsters.
Arteriosclerosis
Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-?, and indoleamine 2,3-dioxygenase.
Arthritis
Addition of an indoleamine-2,3,-dioxygenase inhibitor to B cell depletion therapy blocks autoreactive B cell activation and recurrence of arthritis.
Arthritis
Amelioration of Rat Collagen-induced Arthritis through CD4+ T Cells Apoptosis and Synovial Interleukin-17 Reduction by Indoleamine 2,3-dioxygenase Gene Therapy.
Arthritis
Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-Like 2 Antioxidant Pathway.
Arthritis
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.
Arthritis
Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.
Arthritis
Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.
Arthritis, Experimental
A distinct tolerogenic subset of splenic IDO(+)CD11b(+) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collagen-induced arthritis.
Arthritis, Experimental
Amelioration of Rat Collagen-induced Arthritis through CD4+ T Cells Apoptosis and Synovial Interleukin-17 Reduction by Indoleamine 2,3-dioxygenase Gene Therapy.
Arthritis, Experimental
Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase.
Arthritis, Experimental
Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model.
Arthritis, Infectious
Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis.
Arthritis, Psoriatic
Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines.
Arthritis, Rheumatoid
Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis.
Arthritis, Rheumatoid
Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway.
Arthritis, Rheumatoid
Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines.
Aspergillosis
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance.
Asthma
Decreased expression of indolamine 2,3-dioxygenase in childhood allergic asthma and its inverse correlation with fractional concentration of exhaled nitric oxide.
Asthma
Inhibition of experimental asthma by indoleamine 2,3-dioxygenase.
Asthma
Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges.
Asthma
Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts.
Asthma
Relationships of indoleamine 2,3-dioxygenase activity and cofactors with asthma and nasal polyps.
Asthma
Th17/Treg imbalance is associated with reduced indoleamine 2,3 dioxygenase activity in childhood allergic asthma.
Astrocytoma
Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.
Astrocytoma
Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels.
Astrocytoma
Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Astrocytoma
Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.
Atherosclerosis
Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.
Atherosclerosis
Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes.
Atherosclerosis
Elevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis.
Atherosclerosis
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Atherosclerosis
Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study.
Atherosclerosis
Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production.
Atherosclerosis
Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development.
Atherosclerosis
Inhibition of indoleamine 2,3-dioxygenase (IDO) promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice.
Atherosclerosis
Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: Evidence from the Young Finns study.
Atherosclerosis
Redox Pioneer: Professor Roland Stocker.
Autoimmune Diseases
Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research.
Autoimmune Diseases
Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat.
Autoimmune Diseases
Limited Effect of Indolamine 2,3-Dioxygenase Expression and Enzymatic Activity on Lupus-Like Disease in B6.Nba2 Mice.
Autoimmune Diseases
Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges.
Autoimmune Diseases
Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts.
Autoimmune Diseases
Potential role of indoleamine 2,3-dioxygenase in primary biliary cirrhosis.
Autoimmune Diseases
Role of indoleamine 2,3-dioxygenase in testicular immune-privilege.
Autoimmune Pancreatitis
Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
Bacteremia
Expression of inflammation-associated genes in circulating leukocytes and activity of indoleamine-2,3-dioxygenase in dairy cattle with acute puerperal metritis and bacteremia.
Bacterial Infections
Immunological paradigms and the pathogenesis of ovine chlamydial abortion.
Bacterial Infections
Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.
Boutonneuse Fever
Intralesional expression of mRNA of interferon- gamma , tumor necrosis factor- alpha , interleukin-10, nitric oxide synthase, indoleamine-2,3-dioxygenase, and RANTES is a major immune effector in Mediterranean spotted fever rickettsiosis.
Brain Abscess
Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase.
Brain Injuries
Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation.
Brain Injuries
Neuroprotective effects of human umbilical cord-derived mesenchymal stem cells on periventricular leukomalacia-like brain injury in neonatal rats.
Brain Injuries
Overexpression of kynurenic acid and 3-hydroxyanthranilic acid after rat traumatic brain injury.
Brain Ischemia
Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.
Brain Ischemia
Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation.
Brain Ischemia
Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation.
Brain Neoplasms
A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins.
Brain Neoplasms
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Brain Neoplasms
Imaging Correlates of Differential Expression of Indoleamine 2,3-Dioxygenase in Human Brain Tumors.
Brain Neoplasms
The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.
Breast Neoplasms
Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.
Breast Neoplasms
Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.
Breast Neoplasms
Breast cancer: Occluded role of mitochondria N-acetylserotonin/melatonin ratio in co-ordinating pathophysiology.
Breast Neoplasms
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
Breast Neoplasms
Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
Breast Neoplasms
Codelivered Chemotherapeutic Doxorubicin via a Dual-Functional Immunostimulatory Polymeric Prodrug for Breast Cancer Immunochemotherapy.
Breast Neoplasms
Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle.
Breast Neoplasms
Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.
Breast Neoplasms
Expression of Programmed cell death protein 1 (PD-1) and Indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer.
Breast Neoplasms
Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients.
Breast Neoplasms
Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase.
Breast Neoplasms
High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
Breast Neoplasms
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Breast Neoplasms
IDO Inhibition Facilitates Antitumor Immunity of V?9V?2 T Cells in Triple-Negative Breast Cancer.
Breast Neoplasms
Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Breast Neoplasms
Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells.
Breast Neoplasms
Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan.
Breast Neoplasms
Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer.
Breast Neoplasms
Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Breast Neoplasms
Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase.
Breast Neoplasms
Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Breast Neoplasms
Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Breast Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Breast Neoplasms
Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
Breast Neoplasms
Type III TGF-? receptor downregulation generates an immunotolerant tumor microenvironment.
Breast Neoplasms
[Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer]
Breast Neoplasms
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Breast Neoplasms
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
Breast Neoplasms
[Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy]
Breast Neoplasms
[Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer]
Carcinogenesis
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Carcinogenesis
Cell intrinsic & extrinsic factors in cervical carcinogenesis.
Carcinogenesis
Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.
Carcinogenesis
FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Carcinogenesis
Inhibitory effects of a selective prostaglandin E2 receptor antagonist RQ-15986 on inflammation-related colon tumorigenesis in APC-mutant rats.
Carcinogenesis
Kynurenine emerges from the shadows - Current knowledge on its fate and function.
Carcinogenesis
Recent advances in small molecule based cancer immunotherapy.
Carcinogenesis
The deletion of tryptophan peroxidase activity during dye carcinogenesis.
Carcinogenesis
The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Carcinogenesis
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway.
Carcinoma
Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma.
Carcinoma
CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase (IDO) in basal cell carcinoma keratinocytes.
Carcinoma
Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.
Carcinoma
Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment.
Carcinoma
Exosomes-carrying Epstein-Barr virus-encoded small RNA-1 induces indoleamine 2, 3-dioxygenase expression in tumor-infiltrating macrophages of oral squamous-cell carcinomas and suppresses T-cell activity by activating RIG-I/IL-6/TNF-? pathway.
Carcinoma
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.
Carcinoma
Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas.
Carcinoma
Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix.
Carcinoma
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Carcinoma
Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests.
Carcinoma
Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Carcinoma
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Carcinoma
Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Carcinoma
Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma.
Carcinoma
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Carcinoma
Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways.
Carcinoma
Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma.
Carcinoma
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.
Carcinoma
Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma.
Carcinoma
Prognostic value of tumour-infiltrating CD8+?lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Carcinoma
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Carcinoma
SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells.
Carcinoma
Targeting the IDO-BCL2A1-Cytochrome c Pathway Promotes Apoptosis in Oral Squamous Cell Carcinoma.
Carcinoma
The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma.
Carcinoma
The immunoregulatory mechanisms of carcinoma for its survival and development.
Carcinoma
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
Carcinoma
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.
Carcinoma
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.
Carcinoma
[Inhibitory Effect of Feiji Recipe on IDO Induced Immune Escape on the Murine Model of Lewis Lung Carcinoma].
Carcinoma
[Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma]
Carcinoma, Basal Cell
CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase (IDO) in basal cell carcinoma keratinocytes.
Carcinoma, Ehrlich Tumor
Dual effects of indoleamine 2,3-dioxygenase inhibitors on the therapeutic effects of cyclophosphamide and cycloplatam on Ehrlich ascites tumor in mice.
Carcinoma, Hepatocellular
Effect of potent antiglucocorticoids on dexamethasone induced enzymes in cultured hepatoma and rat liver cells.
Carcinoma, Hepatocellular
Effects of exogenous histones upon the induction of tryptophan pyrrolase and tyrosine transaminase in liver and Morris hepatomas.
Carcinoma, Hepatocellular
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Glucocorticoid receptors in Morris hepatomas and host liver and the correlation of biological activity with receptor levels.
Carcinoma, Hepatocellular
Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation.
Carcinoma, Hepatocellular
Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Metabolic adaptations in rat hepatomas. II. Tryptophan pyrrolase and tyrosine alpha-ketoglutarate transaminase.
Carcinoma, Hepatocellular
METABOLIC ADAPTATIONS IN RAT HEPATOMAS. VI. SUBSTRATE-HORMONE RELATIONSHIPS IN TRYPTOPHAN PYRROLASE INDUCTION.
Carcinoma, Hepatocellular
Pretranslational control of tryptophan oxygenase levels in Morris hepatoma and host liver.
Carcinoma, Hepatocellular
Regulation of gene expression in rat hepatocytes and hepatoma cells by insulin: quantitation of messenger ribonucleic acid's coding for tyrosine aminotransferase, tryptophan oxygenase, and phosphoenolpyruvate carboxykinase.
Carcinoma, Hepatocellular
Tryptophan oxygenase in the liver and Albert hepatoma in mice.
Carcinoma, Hepatocellular
TRYPTOPHAN PYRROLASE ACTIVITY IN TRANSPLANTED "MINIMAL-DEVIATION" HEPATOMAS.
Carcinoma, Hepatocellular
[On tryptophan pyrrolase activity in minimal hepatomas of C3HA mice under the effects of cortisone]
Carcinoma, Hepatocellular
[Substrate and hormonal induction of tryptophan pyrrolase detected in hepatoma 22a cells during transplantation to C3HA mice immunized with syngeneic liver antigens]
Carcinoma, Hepatocellular
[Tryptophan pyrrolase activity in the liver and in some transplantable C3HA mouse hepatomas]
Carcinoma, Lewis Lung
[Inhibitory Effect of Feiji Recipe on IDO Induced Immune Escape on the Murine Model of Lewis Lung Carcinoma].
Carcinoma, Non-Small-Cell Lung
Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Carcinoma, Non-Small-Cell Lung
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Carcinoma, Non-Small-Cell Lung
Induction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Carcinoma, Non-Small-Cell Lung
NK cell-based therapeutics for lung cancer.
Carcinoma, Non-Small-Cell Lung
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance.
Carcinoma, Ovarian Epithelial
Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-?B signaling in vitro.
Carcinoma, Renal Cell
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Carcinoma, Renal Cell
Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma.
Carcinoma, Squamous Cell
Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment.
Carcinoma, Squamous Cell
Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests.
Carcinoma, Squamous Cell
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Carcinoma, Squamous Cell
Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways.
Carcinoma, Squamous Cell
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma.
Carcinoma, Squamous Cell
The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
Carcinoma, Squamous Cell
[Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma]
Cardiovascular Diseases
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
Cardiovascular Diseases
The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: immune homeostatic mechanisms in the artery wall.
Carotid Artery Diseases
Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: Evidence from the Young Finns study.
Cataract
Elevated Expression of indoleamine 2,3-dioxygenase (IDO) and accumulation of kynurenic acid in the pathogenesis of STZ-induced diabetic cataract in Wistar rats.
Cataract
Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens.
Cataract
Kynurenine inhibits fibroblast growth factor 2-mediated expression of crystallins and MIP26 in lens epithelial cells.
Cataract
Regulation of indoleamine 2,3-dioxygenase, the first enzyme in UV filter biosynthesis in the human lens. Relevance for senile nuclear cataract.
Cataract
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Central Nervous System Infections
Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation.
Central Nervous System Neoplasms
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Cerebral Infarction
Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice.
Chlamydia Infections
Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures.
Cholera
Indoleamine 2,3-dioxygenase Expression and Functional Activity in Dendritic Cells Exposed to Cholera Toxin.
Chronic Periodontitis
Indoleamine 2,3-dioxygenase expression and regulation in chronic periodontitis.
Coinfection
Herpes simplex virus co-infection-induced Chlamydia trachomatis persistence is not mediated by any known persistence inducer or anti-chlamydial pathway.
Colitis
Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis.
Colitis
Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production.
Colitis
Induction of Indoleamine 2,3-dioxygenase by Pre-treatment with Poly(I:C) May Enhance the Efficacy of MSC Treatment in DSS-induced Colitis.
Colitis
Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.
Colitis
Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation.
Colitis
Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice.
Colitis
Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis.
Colitis
The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN-? and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase.
Colitis
Xeno-Free Condition Enhances Therapeutic Functions of Human Wharton's Jelly-Derived Mesenchymal Stem Cells against Experimental Colitis by Upregulated Indoleamine 2,3-Dioxygenase Activity.
Colitis, Ulcerative
Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
Colitis, Ulcerative
Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
Colonic Neoplasms
Celastrol Suppresses Tryptophan Catabolism in Human Colon Cancer Cells as Revealed by Metabolic Profiling and Targeted Metabolite Analysis.
Colonic Neoplasms
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Colonic Neoplasms
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.
Colorectal Neoplasms
(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells.
Colorectal Neoplasms
Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy.
Colorectal Neoplasms
Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
Colorectal Neoplasms
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.
Colorectal Neoplasms
Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
Colorectal Neoplasms
Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
Colorectal Neoplasms
Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy.
Colorectal Neoplasms
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Colorectal Neoplasms
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
Colorectal Neoplasms
Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive In Vitro Analysis on Patient-Derived Tumor Models.
Communicable Diseases
Persistent infectious diseases say - IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy.
Communicable Diseases
Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases.
Coronary Artery Disease
Dysregulation of Tryptophan Catabolism in Metabolic Syndrome.
Coronary Artery Disease
Immunomodulatory effects in vitro of vitamin K antagonist acenocoumarol.
Coronary Artery Disease
Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease.
Coronary Artery Disease
Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease.
Coronary Disease
Plasma indoleamine 2,3-dioxygenase concentration is increased in hemodialysis patients and may contribute to the pathogenesis of coronary heart disease.
Crohn Disease
Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact.
Crohn Disease
Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
Crohn Disease
Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
Cystic Fibrosis
Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines.
Cytomegalovirus Infections
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance.
Dementia
Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia.
Dengue
Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function.
Dengue
Neopterin levels and Kyn/Trp ratios were significantly increased in dengue virus patients and subsequently decreased after recovery.
Diabetes Mellitus
Altered Indoleamine 2,3-Dioxygenase Production and Its Association to Inflammatory Cytokines in Peripheral Blood Mononuclear Cells Culture of Type 2 Diabetes Mellitus.
Diabetes Mellitus
RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus.
Diabetes Mellitus
The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus.
Diabetes Mellitus, Experimental
[Hormonal regulation of enzymatic activity. II. Changes of tryptophan peroxidase activity in the rat liver tissue, produced by the amount of glucose, alloxan diabetes and ethionine]
Diabetes Mellitus, Type 1
Effect of Probiotic Administration on Serum Tryptophan Metabolites in Pediatric Type 1 Diabetes Patients.
Diabetes Mellitus, Type 1
The kinetics of plasmacytoid dendritic cell accumulation in the pancreas of the NOD mouse during the early phases of insulitis.
Diabetes Mellitus, Type 1
The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes.
Diabetes Mellitus, Type 2
Altered Indoleamine 2,3-Dioxygenase Production and Its Association to Inflammatory Cytokines in Peripheral Blood Mononuclear Cells Culture of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: Role of indoleamine 2,3-dioxygenase and programmed death-1.
Diabetes Mellitus, Type 2
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
Diabetic Nephropathies
Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: Role of indoleamine 2,3-dioxygenase and programmed death-1.
Diabetic Nephropathies
IDO1 as a new immune biomarker for diabetic nephropathy and its correlation with immune cell infiltration.
Diabetic Nephropathies
Increased indoleamine 2,3-dioxygenase activity in type 2 diabetic nephropathy.
Diabetic Retinopathy
Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients.
Diabetic Retinopathy
Evaluation of the andrographolides role and its indoleamine 2,3-dioxygenase inhibitory potential and attendant molecular mechanism against STZ-induced diabetic rats.
Encephalitis
Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response.
Encephalitis
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis.
Encephalitis, Japanese
Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses.
Encephalomyelitis
Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Correction: The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model.
Encephalomyelitis
Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.
Encephalomyelitis
Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Encephalomyelitis
Murine endometrial-derived mesenchymal stem cells suppress experimental autoimmune encephalomyelitis depending on indoleamine-2,3-dioxygenase expression.
Encephalomyelitis
The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model.
Encephalomyelitis, Autoimmune, Experimental
Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Correction: The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model.
Encephalomyelitis, Autoimmune, Experimental
Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Encephalomyelitis, Autoimmune, Experimental
Murine endometrial-derived mesenchymal stem cells suppress experimental autoimmune encephalomyelitis depending on indoleamine-2,3-dioxygenase expression.
Encephalomyelitis, Autoimmune, Experimental
The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model.
Endometrial Neoplasms
Comparison of preoperative serum neopterin, periostin, indoleamine 2,3-dioxygenase, YKL-40, and tenascin-C levels with current tumor markers for early-stage endometrial cancer.
Endometrial Neoplasms
Expression of immune checkpoint molecules in endometrial carcinoma.
Endometrial Neoplasms
Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
Endometrial Neoplasms
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
Endometrial Neoplasms
Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.
Endometrial Neoplasms
Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Endometrial Neoplasms
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
Endometriosis
Immunosuppressive macrophages induced by IDO1 promote the growth of endometrial stromal cells in endometriosis.
Endometriosis
Indoleamine 2,3-dioxygenase suppresses the cytotoxicity of 1 NK cells in response to ectopic endometrial stromal cells in endometriosis.
Endometriosis
Indoleamine 2,3-dioxygenase-1 (IDO1) in human endometrial stromal cells induces macrophage tolerance through interleukin-33 in the progression of endometriosis.
Endometriosis
Menstrual blood-derived stromal stem cells from women with and without endometriosis reveal different phenotypic and functional characteristics.
Endotoxemia
Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis.
Endotoxemia
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Endotoxemia
Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia.
Eosinophilia
Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan.
Ependymoma
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Epilepsy
Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy.
Epilepsy
Adjuvant indoleamine 2,3-dioxygenase enzyme inhibition for comprehensive management of epilepsy and comorbid depression.
Epilepsy
Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression.
Epilepsy
Evidence in support of using a neurochemistry approach to identify therapy for both epilepsy and associated depression.
Epilepsy
Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy.
Epilepsy
Managing epilepsy-associated depression: Serotonin enhancers or serotonin producers?
Epilepsy, Generalized
Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy.
Epilepsy, Temporal Lobe
Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy.
Epstein-Barr Virus Infections
Epstein-Barr Virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/MAPK and NF-?B pathways: impairment in T cell functions.
Epstein-Barr Virus Infections
Exosomes-carrying Epstein-Barr virus-encoded small RNA-1 induces indoleamine 2, 3-dioxygenase expression in tumor-infiltrating macrophages of oral squamous-cell carcinomas and suppresses T-cell activity by activating RIG-I/IL-6/TNF-? pathway.
Esophageal Neoplasms
p38 predicts depression and poor outcome in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Esophageal Squamous Cell Carcinoma
Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
[Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma]
Fatty Liver
Studies on tryptophan pyrrolase in carbon tetrachloride induced fatty liver. Tryptophan pyrrolase activity as a measure of the therapeutic effect of drugs on hepatic injury.
Fetal Growth Retardation
Endothelial indoleamine 2,3-dioxygenase-1 regulates the placental vascular tone and is deficient in intrauterine growth restriction and pre-eclampsia.
Fibrosarcoma
IL-4 and IL-13 regulate the induction of indoleamine 2,3-dioxygenase activity and the control of Toxoplasma gondii replication in human fibroblasts activated with IFN-gamma.
Flavivirus Infections
Flavivirus infection induces indoleamine 2,3-dioxygenase in human monocyte-derived macrophages via tumor necrosis factor and NF-?B.
Food Hypersensitivity
Low indoleamine 2,3-dioxygenase activity in persistent food allergy in children.
Gastrointestinal Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Gastrointestinal Stromal Tumors
Role of Immune Microenvironment in Gastrointestinal Stromal Tumors.
Gestational Trophoblastic Disease
Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches.
Glioblastoma
Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP?.
Glioblastoma
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Glioblastoma
Establishment of T-helper type 1- and T-helper type 2-like human Toxoplasma antigen-specific T-cell clones.
Glioblastoma
Induction of toxoplasmostasis in a human glioblastoma by interferon gamma.
Glioblastoma
Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus.
Glioblastoma
Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma.
Glioblastoma
PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Glioblastoma
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.
Glioma
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
Glioma
Expression of Indoleamine 2,3-dioxygenase and Correlation with Pathological Malignancy in Gliomas.
Glioma
Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes.
Glioma
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy.
Glioma
Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
Glioma
Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
Glioma
PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Glioma
Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry.
Glioma
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Glioma
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Glioma
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Glioma
The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.
Glomerulonephritis, IGA
Indoleamine 2,3-Dioxygenase (IDO) Regulates Th17/Treg Immunity in Experimental IgA Nephropathy.
Glomerulonephritis, IGA
The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model.
Gout
Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines.
Graft vs Host Disease
A paradoxical pattern of indoleamine 2,3-dioxygenase expression in the colon tissues of patients with acute graft-versus-host disease.
Graft vs Host Disease
IDO in Human Gut Graft-vs-Host Disease.
Graft vs Host Disease
Increased plasma indoleamine 2,3-dioxygenase activity and interferon-? levels correlate with the severity of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Graft vs Host Disease
Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance?
Graft vs Host Disease
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality.
Graft vs Host Disease
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.
Graft vs Host Disease
Potential immunosuppressive function of plasma indoleamine 2,3-dioxygenase in patients with aGVHD after allo-HSCT.
Graft vs Host Disease
Vascular alterations in a murine model of acute graft-versus-host disease are associated with decreased serum levels of adiponectin and an increased activity and vascular expression of indoleamine 2,3-dioxygenase.
Graft vs Host Disease
Vascular Alterations in a Murine Model of Acute Graft-Versus-Host Disease Are Associated With Decreased Serum Levels of Adiponectin and an Increased Activity and Vascular Expression of Indoleamine 2,3-Dioxygenase.
Granuloma
Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection.
Granulomatous Disease, Chronic
Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease.
Granulomatous Disease, Chronic
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages.
Hantavirus Infections
Indoleamine 2,3-dioxygenase activity is associated with regulatory T cell response in acute Puumala hantavirus infection.
Head and Neck Neoplasms
Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virus-Related Head and Neck Cancer.
Heart Defects, Congenital
[Value of indoleamine 2,3-dioxygenase in diagnosis of systemic inflammatory response syndrome after cardiopulmonary bypass in children with congenital heart disease].
Hemangioma
Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution.
Hemangioma
Immune response: A possible role in the pathophysiology of hemangioma.
Hematologic Neoplasms
Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype.
Hematologic Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Hemophilia A
Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice.
Hemorrhagic Fever with Renal Syndrome
High activity of indoleamine 2,3-dioxygenase is associated with renal insufficiency in Puumala hantavirus induced nephropathia epidemica.
Hepatic Encephalopathy
Role of the indoleamine-2,3-dioxygenase/kynurenine pathway of tryptophan metabolism in behavioral alterations in a hepatic encephalopathy rat model.
Hepatic Encephalopathy
The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy in animal models of fulminant hepatic failure.
Hepatitis
Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells.
Hepatitis
The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO).
Hepatitis
Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo.
Hepatitis B
Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination.
Hepatitis B
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells.
Hepatitis B
Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.
Hepatitis B
Possible benefits of the targeting of indoleamine 2,3-dioxygenase (IDO) in hepatitis B vaccination.
Hepatitis B
Recombinant adenovirus with human indoleamine-2,3-dioxygenase and hepatitis B virus preS was constructed and expressed in HepG2 cells.
Hepatitis B
Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo.
Hepatitis B, Chronic
[Immunosuppressive effect of indoleamine 2, 3-dioxygenase on T cells in patients with chronic hepatitis B]
Hepatitis B, Chronic
[Indoleamine-2,3-dioxygenase and the immune microenvironment of chronic hepatitis B patients.]
Hepatitis C
Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.
Hepatitis C
Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients.
Hepatitis C
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis.
Hepatitis C
Induction of indoleamine 2,3-dioxygenase in vivo by IFN-con1.
Hepatitis C
Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C.
Hepatitis C
Serotonin - kynurenine hypothesis of depression: historical overview and recent developments.
Hepatitis C
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.
Hepatitis C, Chronic
Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-? 2a treatment.
Hepatitis C, Chronic
Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.
Herpes Simplex
Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2,3-dioxygenase.
Herpes Simplex
Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus.
Herpes Simplex
Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.
HIV Infections
Combination antiretroviral therapy and indoleamine 2,3-dioxygenase in HIV infections: challenges and new opportunities.
HIV Infections
Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO.
HIV Infections
Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia.
HIV Infections
How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation.
HIV Infections
Parameters of soluble immune activation in vivo correlate negatively with the proliferative capacity of peripheral blood mononuclear cells in vitro in HIV-infected patients.
HIV Infections
Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients.
HIV Infections
Tryptophan depletion in context of the inflammatory and general nutritional status of a low-income South African HIV-infected population.
Hodgkin Disease
Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study.
Huntington Disease
Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Huntington Disease
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Huntington Disease
Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
Huntington Disease
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Huntington Disease
Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
Hydatidiform Mole
Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches.
Hyperbilirubinemia, Neonatal
Sn-protoporphyrin rapidly and markedly enhances the heme saturation of hepatic tryptophan pyrrolase. Evidence that this synthetic metalloporphyrin increases the functional content of heme in the liver.
Hyperglycemia
Fibroblast Cell-Based Therapy for Experimental Autoimmune Diabetes.
Hypersensitivity
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.
Hypersensitivity
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.
Hypersensitivity
Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus.
Hypersensitivity
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Hypersensitivity
The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy.
Hypersensitivity
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance.
Hypersensitivity
Virus Infections Incite Pain Hypersensitivity by Inducing Indoleamine 2,3 Dioxygenase.
Hypersensitivity
[DNAase I hypersensitivity of the 1,5'-flanking region of the tryptophan oxygenase gene in recombinant DNA and chromatin reconstituted with it]
Hypertension, Pulmonary
Endothelial Indoleamine 2,3-Dioxygenase Protects against Development of Pulmonary Hypertension.
Hyperthyroidism
Influence of non-steroidal anti-inflammatory compounds on the hepatic tryptophan pyrrolase activity in hypo- and hyperthyroid rats.
Hyperthyroidism
Role of thyroxine in the postnatal development of rat hepatic tryptophan oxygenase and ornithine aminotransferase.
Hypokinesia
The effect of space flight on the board of the satellite Cosmos 2044 on plasma hormone levels and liver enzyme activities of rats.
Hypotension
Regulation of vascular tone and blood pressure by singlet molecular oxygen in inflammation.
Immune Reconstitution Inflammatory Syndrome
Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis.
Immune System Diseases
Indoleamine 2,3-Dioxygenase, Tryptophan Catabolism, and Mycobacterium avium subsp. paratuberculosis: a Model for Chronic Mycobacterial Infections.
Immune System Diseases
Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells.
indoleamine 2,3-dioxygenase deficiency
Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation.
indoleamine 2,3-dioxygenase deficiency
Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines.
Infections
A crucial role for tryptophan catabolism at the host/Candida albicans interface.
Infections
A First Plasmodium vivax Natural Infection Induces Increased Activity of the Interferon Gamma-Driven Tryptophan Catabolism Pathway.
Infections
A potential role for indoleamine 2,3-dioxygenase (IDO) in Rhodococcus equi infection.
Infections
Activation of the tryptophan/serotonin pathway is associated with severity and predicts outcomes in pneumonia: results of a long-term cohort study.
Infections
An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function.
Infections
Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.
Infections
Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases.
Infections
Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.
Infections
Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.
Infections
Brain virus burden and indoleamine-2,3-dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6-chloro-2',3'-dideoxyguanosine.
Infections
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.
Infections
Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection.
Infections
Decreased IDO1 Dependent Tryptophan Metabolism in Aged Lung during Influenza.
Infections
Early cytokine production is associated with protection from murine cerebral malaria.
Infections
Effects of Schistosoma mansoni infection on induction of tryptophan oxygenase in mouse livers.
Infections
Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase.
Infections
Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1.
Infections
Expression of interferon regulatory factors and indoleamine 2,3-dioxygenase in Chlamydia trachomatis-infected synovial fibroblasts.
Infections
Free iron ions decrease indoleamine 2,3-dioxygenase expression and reduce IFNgamma-induced inhibition of Chlamydia trachomatis infection.
Infections
Helicobacter pylori-induced indoleamine 2,3-dioxygenase activity in vivo is regulated by TGFB1 and CTLA4 polymorphisms.
Infections
Heme oxygenase-1 activity is involved in the control of Toxoplasma gondii infection in the lung of BALB/c and C57BL/6 and in the small intestine of C57BL/6 mice.
Infections
Histoplasma capsulatum preferentially induces IDO in the lung.
Infections
HIV-1 Tat Protein Induces the Production of IDO in Human Monocyte Derived-Dendritic Cells through a Direct Mechanism: Effect on T Cells Proliferation.
Infections
Hypoxia abrogates antichlamydial properties of IFN-{gamma} in human fallopian tube cells in vitro and ex vivo.
Infections
Immunity and tolerance to Aspergillus fumigatus.
Infections
Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism.
Infections
Immunopathogenesis of cerebral malaria.
Infections
Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following Toxoplasma gondii infection.
Infections
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Infections
Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium.
Infections
Increased mRNA expression of kynurenine pathway enzymes in human placentae exposed to bacterial endotoxin.
Infections
Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation.
Infections
Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge.
Infections
Indoleamine 2,3-dioxygenase activity is associated with regulatory T cell response in acute Puumala hantavirus infection.
Infections
Indoleamine 2,3-dioxygenase expression is associated with chronic rhinosinusitis: review of the evidence.
Infections
Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages.
Infections
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host.
Infections
Indoleamine 2,3-dioxygenase is differentially expressed by different white blood cell populations of rhesus macaques (Macaca mulatta).
Infections
Indoleamine 2,3-Dioxygenase Is Involved in the Inflammation Response of Corneal Epithelial Cells to Aspergillus fumigatus Infections.
Infections
Indoleamine 2,3-dioxygenase is regulated by IFN-gamma in the mouse placenta during Listeria monocytogenes infection.
Infections
Indoleamine 2,3-Dioxygenase, Tryptophan Catabolism, and Mycobacterium avium subsp. paratuberculosis: a Model for Chronic Mycobacterial Infections.
Infections
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection.
Infections
Induction of indoleamine 2,3-dioxygenase by uropathogenic bacteria attenuates innate responses to epithelial infection.
Infections
Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.
Infections
Influenza A virus infection induces indoleamine 2,3-dioxygenase (IDO) expression and modulates subsequent inflammatory mediators in nasal epithelial cells.
Infections
Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia.
Infections
Inhibition of increased indoleamine 2,3-dioxygenase activity attenuates Toxoplasma gondii replication in the lung during acute infection.
Infections
Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection.
Infections
Interferon-beta induction by Chlamydia pneumoniae in human smooth muscle cells.
Infections
Interplay between IDO1 and iNOS in human retinal pigment epithelial cells.
Infections
Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
Infections
Isolating vessels from the mouse brain for gene expression analysis using laser capture microdissection.
Infections
L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase.
Infections
Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.
Infections
Lysophosphatidylcholine exacerbates Leishmania major-dendritic cell infection through interleukin-10 and a burst in arginase1 and indoleamine 2,3-dioxygenase activities.
Infections
Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression.
Infections
Neopterin in HIV-1 infection.
Infections
Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures.
Infections
Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells.
Infections
Pulmonary paracoccidioidomycosis in AhR deficient hosts is severe and associated with defective Treg and Th22 responses.
Infections
Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches.
Infections
Regulation of kynurenine biosynthesis during influenza virus infection.
Infections
Restriction of Chlamydia pneumoniae replication in human dendritic cell by activation of indoleamine 2,3-dioxygenase.
Infections
Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation.
Infections
Schistosoma mansoni and Schistosoma japonicum: effects of infection on induction of tryptophan oxygenase in mouse livers.
Infections
Serum tryptophan and its metabolites in female dogs undergoing ovariohysterectomy as treatment of pyometra or as elective spay surgery.
Infections
Severe Tryptophan Starvation Blocks Onset of Conventional Persistence and Reduces Reactivation of Chlamydia trachomatis.
Infections
Systemic treatment with CpG-B after sublethal rickettsial infection induces mouse death through indoleamine 2,3-dioxygenase (IDO).
Infections
Th17 and regulatory T cells: implications for AIDS pathogenesis.
Infections
The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO).
Infections
The end of the road for the tryptophan depletion concept in pregnancy and infection.
Infections
The IDO1-induced kynurenines play a major role in the antimicrobial effect of human myeloid cells against Listeria monocytogenes.
Infections
Tolerogenic Plasmacytoid Dendritic Cells Control Paracoccidioides brasiliensis Infection by Inducting Regulatory T Cells in an IDO-Dependent Manner.
Infections
Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions.
Infections
Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.
Infections
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Infections
Two New Tryptophan Derivatives from the Seed Kernels of Entada rheedei: Effects on Cell Viability and HIV Infectivity.
Infections
Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus infection by indoleamine 2,3-dioxygenase in rat aortic transplant model.
Inflammatory Bowel Diseases
Indoleamine 2,3-dioxygenase and regulatory t cells in intestinal mucosa in children with inflammatory bowel disease.
Inflammatory Bowel Diseases
Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
Inflammatory Bowel Diseases
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease.
Inflammatory Bowel Diseases
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
Influenza, Human
Assessment of neopterin and indoleamine 2,3-dioxygenase activity in patients with seasonal influenza: A pilot study.
Influenza, Human
Attenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocycline.
Influenza, Human
Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.
Influenza, Human
Decreased IDO1 Dependent Tryptophan Metabolism in Aged Lung during Influenza.
Influenza, Human
Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection.
Influenza, Human
Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.
Influenza, Human
Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge.
Influenza, Human
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection.
Influenza, Human
Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.
Influenza, Human
Influenza A virus infection induces indoleamine 2,3-dioxygenase (IDO) expression and modulates subsequent inflammatory mediators in nasal epithelial cells.
Influenza, Human
Influenza virus induces expression of antioxidant genes in human epithelial cells.
Influenza, Human
Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia.
Influenza, Human
Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection.
Insulin Resistance
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Insulin Resistance
Serotonin - kynurenine hypothesis of depression: historical overview and recent developments.
Intestinal Diseases
Indoleamine 2,3 dioxygenase in intestinal disease.
Iron Deficiencies
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Iron Deficiencies
Rat liver tryptophan pyrrolase activity in iron deficiency.
Iron Deficiencies
Utilization of dietary tryptophan in iron-deficient rats.
Irritable Bowel Syndrome
Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort.
Ischemic Stroke
Serum indoleamine 2,3-dioxygenase and kynurenine aminotransferase enzyme activity in patients with ischemic stroke.
Ischemic Stroke
The novel targets of DL-3-n-butylphthalide predicted by similarity ensemble approach in combination with molecular docking study.
Keratitis
Expression of indoleamine 2,3-dioxygenase in a murine model of Aspergillus fumigatus keratitis.
Keratitis
Indoleamine 2,3-Dioxygenase Regulates Macrophage Recruitment, Polarization and Phagocytosis in Aspergillus Fumigatus Keratitis.
Latent Infection
Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients.
Leishmaniasis
Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of human dendritic cells.
Leishmaniasis
The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection.
Leishmaniasis, Visceral
Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis.
Leprosy, Lepromatous
Indoleamine 2,3-dioxygenase and iron are required for Mycobacterium leprae survival.
Leukemia
Adipose tissue-derived stromal cells retain immunosuppressive and angiogenic activity after coculture with cord blood hematopoietic precursors.
Leukemia
Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators.
Leukemia
Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.
Leukemia
Forced expression of indoleamine-2,3-dioxygenase in human umbilical cord-derived mesenchymal stem cells abolishes their anti-apoptotic effect on leukemia cell lines in vitro.
Leukemia
IFN-? and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Leukemia
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair leukemia-specific immune response by inducing potent T regulatory cells.
Leukemia
Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface.
Leukemia
Synergistic effects of phorbol ester and INF-gamma on the induction of indoleamine 2,3-dioxygenase in THP-1 monocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic Lymphocytic Leukemia Nurse-like cells express the hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.
Leukemia, Lymphocytic, Chronic, B-Cell
Indoleamine 2,3-Dioxygenase Activity and Expression in Patients With Chronic Lymphocytic Leukemia.
Leukemia, Myeloid, Acute
A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.
Leukemia, Myeloid, Acute
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.
Leukemia, Myeloid, Acute
Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.
Leukemia, Myeloid, Acute
Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Leukemia, Myeloid, Acute
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
Leukemia, Myeloid, Acute
Hydrogen-Peroxide Synthesis and LDL-Uptake Controls Immunosuppressive Properties in Monocyte-Derived Dendritic Cells.
Leukemia, Myeloid, Acute
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.
Leukemia, Myeloid, Acute
Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair leukemia-specific immune response by inducing potent T regulatory cells.
Leukemia, Myeloid, Acute
Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.
Leukemia, Myeloid, Acute
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.
Leukemia, Myeloid, Acute
Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype.
Leukemia, Myeloid, Acute
Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
Leukemia, Myeloid, Acute
[Expression and Activity Regulation of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia Cells].
Lichen Planus, Oral
Interferon-? regulates the function of mesenchymal stem cells from oral lichen planus via indoleamine 2,3-dioxygenase activity.
Listeriosis
Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection.
Liver Cirrhosis
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis.
Liver Cirrhosis
The Deficiency of Indoleamine 2,3-Dioxygenase Aggravates the CCl4-Induced Liver Fibrosis in Mice.
Liver Cirrhosis, Biliary
1-Methyl tryptophan, an indoleamine 2,3-dioxygenase inhibitor, attenuates cardiac and hepatic dysfunction in rats with biliary cirrhosis.
Liver Cirrhosis, Biliary
Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Potential role of indoleamine 2,3-dioxygenase in primary biliary cirrhosis.
Liver Diseases
A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases.
Liver Diseases
[Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study]
Liver Neoplasms
Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer.
Liver Neoplasms, Experimental
Messenger RNA activities for two liver enzymes, tyrosine aminotransferase and tryptophan oxygenase, in Morris hepatoma 5123C and 9618A and in HTC cells. Correlation with enzyme activities.
Liver Neoplasms, Experimental
Pretranslational control of tryptophan oxygenase levels in Morris hepatoma and host liver.
Lung Neoplasms
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Lung Neoplasms
Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Lung Neoplasms
Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model.
Lung Neoplasms
Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Lung Neoplasms
GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer.
Lung Neoplasms
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC).
Lung Neoplasms
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Lung Neoplasms
Indoleamine 2,3-Dioxygenase (IDO) Expression in Lung Cancer.
Lung Neoplasms
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.
Lung Neoplasms
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Lung Neoplasms
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Lung Neoplasms
Induction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells.
Lung Neoplasms
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Lung Neoplasms
NK cell-based therapeutics for lung cancer.
Lung Neoplasms
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance.
Lung Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Lupus Erythematosus, Systemic
Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.
Lupus Erythematosus, Systemic
Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
Lymphatic Metastasis
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
Lymphoma
Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience.
Lymphoma
NK cell-based therapeutics for lung cancer.
Lymphoma, B-Cell
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Lymphoma, B-Cell
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Lymphoma, Large B-Cell, Diffuse
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Lymphoma, Large B-Cell, Diffuse
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Lymphoma, Non-Hodgkin
Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
Malaria
Immunopathogenesis of cerebral malaria.
Malaria
Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium.
Malaria
Isolating vessels from the mouse brain for gene expression analysis using laser capture microdissection.
Malaria, Cerebral
Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection is predominantly localised to the vascular endothelium.
Massive Hepatic Necrosis
Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis.
Mastitis
Tryptophan, kynurenine, kynurenic acid concentrations and indoleamine 2,3-dioxygenase activity in serum and milk of dairy cows with subclinical mastitis caused by coagulase-negative staphylococci.
Melanoma
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.
Melanoma
Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
Melanoma
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Melanoma
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Melanoma
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model.
Melanoma
Effect of indoleamine 2,3-dioxygenase expressed by fetal fibroblasts on melanoma cells.
Melanoma
Enzyme activities and metabolites along the kynurenine pathway in mice with Harding-Passey melanoma.
Melanoma
Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
Melanoma
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.
Melanoma
FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients.
Melanoma
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Melanoma
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy.
Melanoma
Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
Melanoma
Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.
Melanoma
Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival.
Melanoma
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Melanoma
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Melanoma
Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment.
Melanoma
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Melanoma
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Melanoma
Mechanisms of local immunosuppression in cutaneous melanoma.
Melanoma
Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction.
Melanoma
Occurrence of indoleamine 2,3-dioxygenase in human cutaneous malignant melanoma.
Melanoma
PD-L1 blockade for cancer treatment: MEDI4736.
Melanoma
Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Melanoma
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Melanoma
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Melanoma
Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy.
Melanoma
Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.
Melanoma
T and NK cells: two sides of tumor immunoevasion.
Melanoma
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Melanoma
The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor ? and interferon ? in metastatic lymph nodes in malignant melanoma.
Melanoma
The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Melanoma
Tryptophan protects human melanoma cells against gamma-interferon and tumour necrosis factor-alpha: a unifying mechanism of action.
Melanoma
Type III TGF-? receptor downregulation generates an immunotolerant tumor microenvironment.
Melanoma
Variable indoleamine 2,3-dioxygenase expression in acral / mucosal melanoma and its possible link to immunotherapy.
Melanoma
[Potential endogenous immunological self-protection of uveal melanoma by indoleamine 2,3-dioxygenase]
Meningitis, Pneumococcal
Inhibition of indoleamine 2,3-dioxygenase prevented cognitive impairment in adult Wistar rats subjected to pneumococcal meningitis.
Mesothelioma
High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
Mesothelioma
The usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma.
Mesothelioma, Malignant
High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
Metabolic Diseases
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Metabolic Syndrome
Lipopolysaccharide-induced brain activation of the indoleamine 2,3-dioxygenase and depressive-like behavior are impaired in a mouse model of metabolic syndrome.
Miosis
[Effect of ethyl-p-nitrophenyl phenylphosphonothiate (EPN) on tryptophan pyrrolase activity in relation to miosis and change in serum cholinesterase activities]
Mouth Neoplasms
Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells.
Multiple Myeloma
Multiple myeloma cell-derived IL-32? increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression.
Multiple Sclerosis
A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells.
Multiple Sclerosis
Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis.
Multiple Sclerosis
Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System.
Multiple Sclerosis, Relapsing-Remitting
Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis.
Muscular Dystrophies, Limb-Girdle
Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways.
Myelodysplastic Syndromes
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.
Myelodysplastic Syndromes
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Myocardial Ischemia
Indoleamine 2,3-dioxygenase and ischemic heart disease: a Mendelian Randomization study.
Myocarditis
Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice.
Nasal Polyps
Indoleamine 2,3-dioxygenase expression is associated with chronic rhinosinusitis with nasal polyps and antrochoanal polyps.
Nasal Polyps
Relationships of indoleamine 2,3-dioxygenase activity and cofactors with asthma and nasal polyps.
Nasopharyngeal Carcinoma
Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation.
Nasopharyngeal Carcinoma
Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes.
Nasopharyngeal Carcinoma
Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells.
Neoplasm Metastasis
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
Neoplasm Metastasis
Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.
Neoplasm Metastasis
Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model.
Neoplasm Metastasis
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy.
Neoplasm Metastasis
Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Neoplasm Metastasis
Immunological environment in colorectal cancer: a computer-aided morphometric study of whole slide digital images derived from tissue microarray.
Neoplasm Metastasis
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Neoplasm Metastasis
Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Neoplasm Metastasis
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Neoplasm Metastasis
Mechanisms of local immunosuppression in cutaneous melanoma.
Neoplasm Metastasis
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
Neoplasm Metastasis
The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor ? and interferon ? in metastatic lymph nodes in malignant melanoma.
Neoplasm Metastasis
Ultrasound-Driven Biomimetic Nanosystem Suppresses Tumor Growth and Metastasis through Sonodynamic Therapy, CO Therapy, and Indoleamine 2,3-Dioxygenase Inhibition.
Neoplasms
(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells.
Neoplasms
(-)-Epigallocatechin gallate suppresses indoleamine 2,3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets.
Neoplasms
A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy.
Neoplasms
A crucial role for tryptophan catabolism at the host/Candida albicans interface.
Neoplasms
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Neoplasms
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Neoplasms
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.
Neoplasms
A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies.
Neoplasms
A new glucocorticoid receptor detected in host rat liver but not in various hepatomas.
Neoplasms
A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Neoplasms
A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Neoplasms
A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils.
Neoplasms
Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenase activity by ethyl pyruvate.
Neoplasms
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.
Neoplasms
Adipose-derived stem cells induced dendritic cells undergo tolerance and inhibit Th1 polarization.
Neoplasms
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
Neoplasms
AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer.
Neoplasms
Alteration in Gene Pair Correlations in Tryptophan Metabolism as a Hallmark in Cancer Diagnosis.
Neoplasms
Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients.
Neoplasms
An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
Neoplasms
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.
Neoplasms
Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.
Neoplasms
Arid5a: A Missing Link between EMT and Tumoral Immune Resistance.
Neoplasms
Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.
Neoplasms
Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy.
Neoplasms
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Neoplasms
Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Neoplasms
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3.
Neoplasms
Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation.
Neoplasms
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Neoplasms
Caffeic acid phenethyl ester protects against photothrombotic cortical ischemic injury in mice.
Neoplasms
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.
Neoplasms
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Neoplasms
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
Neoplasms
Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Neoplasms
Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.
Neoplasms
Catalytic activity of human indoleamine 2,3-dioxygenase (hIDO1) at low oxygen.
Neoplasms
CD4 responses against IDO.
Neoplasms
CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Neoplasms
Cell-Based Identification of New IDO1 Modulator Chemotypes.
Neoplasms
Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity.
Neoplasms
Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy.
Neoplasms
Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
Neoplasms
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.
Neoplasms
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Neoplasms
Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Neoplasms
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.
Neoplasms
Chrysin promotes attenuation of depressive-like behavior and hippocampal dysfunction resulting from olfactory bulbectomy in mice.
Neoplasms
Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
Neoplasms
Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
Neoplasms
Cloning and expression of a cDNA encoding mouse indoleamine 2,3-dioxygenase.
Neoplasms
Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Neoplasms
Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.
Neoplasms
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Neoplasms
Comparison of preoperative serum neopterin, periostin, indoleamine 2,3-dioxygenase, YKL-40, and tenascin-C levels with current tumor markers for early-stage endometrial cancer.
Neoplasms
Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Neoplasms
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Neoplasms
Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.
Neoplasms
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.
Neoplasms
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Neoplasms
Dendritic cell vaccination against ovarian cancer - tipping the Treg/T(H)17 balance to therapeutic advantage?
Neoplasms
Depression-like behavior, hyperglycemia, oxidative stress, and neuroinflammation presented in diabetic mice are reversed by the administration of 1-methyl-3-(phenylselanyl)-1H-indole.
Neoplasms
Design and automated production of 11C-alpha-methyl-l-tryptophan (11C-AMT).
Neoplasms
Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
Neoplasms
Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.
Neoplasms
Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Neoplasms
Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
Neoplasms
Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.
Neoplasms
Different effects of tryptophan 2,3-dioxygenase inhibition on SK-Mel-28 and HCT-8 cancer cell lines.
Neoplasms
Differential effects of the tryptophan metabolite3-hydroxyanthranilic acid on the proliferation of human CD8(+) T cells induced by TCR triggering or homeostatic cytokines.
Neoplasms
Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells.
Neoplasms
Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-gamma and -alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor.
Neoplasms
Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Neoplasms
Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Neoplasms
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.
Neoplasms
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy.
Neoplasms
Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.
Neoplasms
Discovery of potent indoleamine 2,3-dioxygenase (IDO) inhibitor from alkaloids in Picrasma quassioides by virtual screening and in vitro evaluation.
Neoplasms
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2, 3-Dioxygenase with Therapeutic Activity in LLC tumor-bearing Mice.
Neoplasms
DNA regulatory elements for steroid hormones.
Neoplasms
Do regulatory T-cells play a role in AIDS pathogenesis?
Neoplasms
Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation.
Neoplasms
Dual biological effects of the cytokines interleukin-10 and interferon-?.
Neoplasms
Dual effects of indoleamine 2,3-dioxygenase inhibitors on the therapeutic effects of cyclophosphamide and cycloplatam on Ehrlich ascites tumor in mice.
Neoplasms
Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal.
Neoplasms
Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Neoplasms
Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase.
Neoplasms
Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion.
Neoplasms
Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.
Neoplasms
Effect of basic protein from tumor tissue on liver tryptophan pyrrolase activity.
Neoplasms
Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.
Neoplasms
Effects of pentoxifylline, 7-nitroindazole, and imipramine on tumor necrosis factor-? and indoleamine 2,3-dioxygenase enzyme activity in the hippocampus and frontal cortex of chronic mild-stress-exposed rats.
Neoplasms
Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy.
Neoplasms
Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
Neoplasms
Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis.
Neoplasms
Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation.
Neoplasms
Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.
Neoplasms
Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser.
Neoplasms
Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.
Neoplasms
Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells.
Neoplasms
Evaluation of L-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer.
Neoplasms
Exploration of good and bad structural fingerprints for inhibition of indoleamine-2,3-dioxygenase enzyme in cancer immunotherapy using Monte Carlo optimization and Bayesian classification QSAR modeling.
Neoplasms
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.
Neoplasms
Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.
Neoplasms
Expression of Indoleamine 2,3-dioxygenase and Correlation with Pathological Malignancy in Gliomas.
Neoplasms
Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Neoplasms
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Neoplasms
Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests.
Neoplasms
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Neoplasms
Expression of Programmed cell death protein 1 (PD-1) and Indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer.
Neoplasms
Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.
Neoplasms
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Neoplasms
Fish oil ameliorates sickness behavior induced by lipopolysaccharide in aged mice through the modulation of kynurenine pathway.
Neoplasms
Flavivirus infection induces indoleamine 2,3-dioxygenase in human monocyte-derived macrophages via tumor necrosis factor and NF-?B.
Neoplasms
Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.
Neoplasms
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
Neoplasms
Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients.
Neoplasms
FoxP3 and IDO in Canine Melanocytic Tumors.
Neoplasms
FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Neoplasms
FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors.
Neoplasms
From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Neoplasms
Fully automated radiosynthesis of N(1)-[(18)F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging.
Neoplasms
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Neoplasms
Gene silencing of indoleamine 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition.
Neoplasms
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer.
Neoplasms
Glycogen Synthase Kinase-3? (GSK-3?) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-?-induced Indoleamine 2,3-Dioxygenase Expression.
Neoplasms
Haemophilus ducreyi Lipooligosaccharides Induce Expression of the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase via Type I Interferons and Tumor Necrosis Factor Alpha in Human Dendritic Cells.
Neoplasms
Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2.
Neoplasms
Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation.
Neoplasms
High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
Neoplasms
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
Neoplasms
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Neoplasms
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Neoplasms
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Neoplasms
HPV16 E2 protein promotes innate immunity by modulating immunosuppressive status.
Neoplasms
Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways.
Neoplasms
Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms.
Neoplasms
Human Mesenchymal Stem Cells Overexpressing the IL-33 Antagonist Soluble IL-1 Receptor-Like-1 Attenuate Endotoxin-Induced Acute Lung Injury.
Neoplasms
Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation.
Neoplasms
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Neoplasms
Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.
Neoplasms
Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.
Neoplasms
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation.
Neoplasms
IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.
Neoplasms
IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive.
Neoplasms
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Neoplasms
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.
Neoplasms
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development.
Neoplasms
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Neoplasms
IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment.
Neoplasms
IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease.
Neoplasms
IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis.
Neoplasms
IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma.
Neoplasms
IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a.
Neoplasms
IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.
Neoplasms
IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection.
Neoplasms
Imaging Correlates of Differential Expression of Indoleamine 2,3-Dioxygenase in Human Brain Tumors.
Neoplasms
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
Neoplasms
Immune escape as a fundamental trait of cancer: focus on IDO.
Neoplasms
Immune modulation in corneal transplantation.
Neoplasms
Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance.
Neoplasms
Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination.
Neoplasms
Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
Neoplasms
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy.
Neoplasms
Immunohistochemical evaluation of immune cell infiltration in canine gliomas.
Neoplasms
Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Neoplasms
Immunological effects of levamisole in vitro.
Neoplasms
Immunological environment in colorectal cancer: a computer-aided morphometric study of whole slide digital images derived from tissue microarray.
Neoplasms
Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta.
Neoplasms
Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach.
Neoplasms
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.
Neoplasms
Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands.
Neoplasms
Improved Radiosynthesis and Biological Evaluations of L- and D-1-[
Neoplasms
In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.
Neoplasms
Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase (IDO) with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia.
Neoplasms
Increased tryptophan transport in epileptogenic dysembryoplastic neuroepithelial tumors.
Neoplasms
Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Neoplasms
Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
Neoplasms
Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
Neoplasms
Indoleamine 2,3-Dioxygenase (IDO) Expression in Lung Cancer.
Neoplasms
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Neoplasms
Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy.
Neoplasms
Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Neoplasms
Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Neoplasms
Indoleamine 2,3-dioxygenase Affects the Aggressiveness of Intraductal Papillary Mucinous Neoplasms Through Foxp3+CD4+CD25+ T Cells in Peripheral Blood.
Neoplasms
Indoleamine 2,3-dioxygenase and ischemic heart disease: a Mendelian Randomization study.
Neoplasms
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Neoplasms
Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.
Neoplasms
Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.
Neoplasms
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy.
Neoplasms
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.
Neoplasms
Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan.
Neoplasms
Indoleamine 2,3-dioxygenase expression in early keratocyte neoplasia of the lower lip correlates to the degree of cell atypia.
Neoplasms
Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches.
Neoplasms
Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.
Neoplasms
Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival.
Neoplasms
Indoleamine 2,3-dioxygenase expression is associated with chronic rhinosinusitis: review of the evidence.
Neoplasms
Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.
Neoplasms
Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.
Neoplasms
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
Neoplasms
Indoleamine 2,3-dioxygenase in immune suppression and cancer.
Neoplasms
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Neoplasms
Indoleamine 2,3-dioxygenase in tumor induced tolerance.
Neoplasms
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Neoplasms
Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
Neoplasms
Indoleamine 2,3-dioxygenase inhibitors: potential treatment for cancer, sepsis, and more.
Neoplasms
Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A.
Neoplasms
Indoleamine 2,3-dioxygenase is differentially expressed by different white blood cell populations of rhesus macaques (Macaca mulatta).
Neoplasms
Indoleamine 2,3-Dioxygenase Is Not a Pivotal Regulator Responsible for Suppressing Allergic Airway Inflammation through Adipose-Derived Stem Cells.
Neoplasms
Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors.
Neoplasms
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin.
Neoplasms
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.
Neoplasms
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Neoplasms
Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Neoplasms
Indoleamine 2,3-dioxygenase, Tregs and cancer.
Neoplasms
Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Neoplasms
Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival.
Neoplasms
Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer.
Neoplasms
Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: interferon-gamma is the inducer.
Neoplasms
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.
Neoplasms
Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
Neoplasms
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.
Neoplasms
Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices.
Neoplasms
Influence of Donor's Age on Immunomodulatory Properties of Canine Adipose Tissue-Derived Mesenchymal Stem Cells.
Neoplasms
Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2,3-dioxygenase.
Neoplasms
Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virus-Related Head and Neck Cancer.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Neoplasms
Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase in human macrophages inhibits interferon-gamma-induced bacteriostasis but does not abrogate toxoplasmastasis.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.
Neoplasms
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Neoplasms
Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus.
Neoplasms
Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
Neoplasms
Inhibitor of indoleamine-2,3-dioxygenase 1-methyl-D-tryptophan can stimulate the growth of immunogenic tumors.
Neoplasms
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Neoplasms
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Neoplasms
Inhibitory effects of a selective prostaglandin E2 receptor antagonist RQ-15986 on inflammation-related colon tumorigenesis in APC-mutant rats.
Neoplasms
Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade.
Neoplasms
Insights from the predicted structural analysis of carborane substituted withaferin A with Indoleamine - 2,3-dioxygenase as a potent inhibitor.
Neoplasms
Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment.
Neoplasms
Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients.
Neoplasms
Interferon-? and Tumor Necrosis Factor-? Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype.
Neoplasms
Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin.
Neoplasms
Intralesional expression of mRNA of interferon- gamma , tumor necrosis factor- alpha , interleukin-10, nitric oxide synthase, indoleamine-2,3-dioxygenase, and RANTES is a major immune effector in Mediterranean spotted fever rickettsiosis.
Neoplasms
Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
Neoplasms
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.
Neoplasms
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.
Neoplasms
Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling.
Neoplasms
l-Kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species.
Neoplasms
Lack of microbicidal response in human macrophages infected with Parachlamydia acanthamoebae.
Neoplasms
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.
Neoplasms
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment.
Neoplasms
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.
Neoplasms
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.
Neoplasms
Low dose Zebularine treatment enhances immunogenicity of tumor cells.
Neoplasms
Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients.
Neoplasms
Low Levels of Serum Tryptophan Underlie Skeletal Muscle Atrophy.
Neoplasms
Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy.
Neoplasms
Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges.
Neoplasms
Marrying immunotherapy with chemotherapy: why say IDO?
Neoplasms
Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice.
Neoplasms
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
Neoplasms
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.
Neoplasms
Mediating the death of dormant tumor cells.
Neoplasms
Melatonin in cancer patients and in tumor-bearing animals.
Neoplasms
Mesenchymal Stromal Cells Affect Disease Outcomes via Macrophage Polarization.
Neoplasms
Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Neoplasms
Metabolomic Analysis of Gastric Cancer Progression within the Correa's Cascade Using Ultraperformance Liquid Chromatography-Mass Spectrometry.
Neoplasms
Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy.
Neoplasms
Minireview, The oxidative stress-induced niacin sink (OSINS) model for HIV pathogenesis.
Neoplasms
MiR-218 produces anti-tumor effects on cervical cancer cells in vitro.
Neoplasms
Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase.
Neoplasms
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Neoplasms
Modulation of dendritic cell maturation and function by siRNA-bearing 5'-triphosphate.
Neoplasms
Modulation of tumor tolerance in primary central nervous system malignancies.
Neoplasms
Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
Neoplasms
Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients.
Neoplasms
Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma.
Neoplasms
Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts.
Neoplasms
Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.
Neoplasms
Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy.
Neoplasms
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors.
Neoplasms
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle.
Neoplasms
Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment.
Neoplasms
Neuroprotective effects of human umbilical cord-derived mesenchymal stem cells on periventricular leukomalacia-like brain injury in neonatal rats.
Neoplasms
NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha.
Neoplasms
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Neoplasms
NK cell-based therapeutics for lung cancer.
Neoplasms
NK Cell-Dependent Growth Inhibition of Lewis Lung Cancer by Yu-Ping-Feng, an Ancient Chinese Herbal Formula.
Neoplasms
No significant effects of Poly(I:C) on human umbilical cord-derived mesenchymal stem cells in the treatment of B6.MRL-Fas(lpr) mice.
Neoplasms
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.
Neoplasms
NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.
Neoplasms
O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.
Neoplasms
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy.
Neoplasms
Oral Probiotics Ameliorate the Behavioral Deficits Induced by Chronic Mild Stress in Mice via the Gut Microbiota-Inflammation Axis.
Neoplasms
Ovarian Tumor Ascites CD14+ Cells Suppress Dendritic Cell-activated CD4+ T-cell Responses Through IL-10 Secretion and Indoleamine 2,3-Dioxygenase.
Neoplasms
Overcoming Chemoimmunotherapy-Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension.
Neoplasms
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
Neoplasms
Overcoming T Cell Exhaustion via Immune Checkpoint Modulation with a Dendrimer-Based Hybrid Nanocomplex.
Neoplasms
Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Neoplasms
p38 predicts depression and poor outcome in esophageal cancer.
Neoplasms
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Neoplasms
PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Neoplasms
PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
Neoplasms
PEG-Poly(1-Methyl-l-Tryptophan)-Based Polymeric Micelles as Enzymatically Activated Inhibitors of Indoleamine 2,3-Dioxygenase.
Neoplasms
Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Neoplasms
pH-Sensitive Molecular-Switch-Containing Polymer Nanoparticle for Breast Cancer Therapy with Ferritinophagy-Cascade Ferroptosis and Tumor Immune Activation.
Neoplasms
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Neoplasms
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Neoplasms
Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy.
Neoplasms
Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy.
Neoplasms
Physical state, expression and regulation of two glucocorticoid-controlled genes on bovine papilloma virus vectors.
Neoplasms
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.
Neoplasms
Placenta-derived multipotent mesenchymal stromal cells: a promising potential cell-based therapy for canine inflammatory brain disease.
Neoplasms
Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Neoplasms
Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.
Neoplasms
Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan.
Neoplasms
Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors.
Neoplasms
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
Neoplasms
Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.
Neoplasms
Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.
Neoplasms
Proposed mechanisms for oligonucleotide IMT504 induced diabetes reversion in a mouse model of immunodependent diabetes.
Neoplasms
Prostaglandin D2 is a novel repressor of IFN? induced indoleamine-2,3-dioxygenase via the DP1 receptor and cAMP pathway.
Neoplasms
Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.
Neoplasms
Quantification of tryptophan transport and metabolism in lung tumors using PET.
Neoplasms
Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone.
Neoplasms
Rational design of indoleamine 2,3-dioxygenase inhibitors.
Neoplasms
Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
Neoplasms
Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Neoplasms
Regulatory T cells move in when gliomas say "I Do".
Neoplasms
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma.
Neoplasms
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice.
Neoplasms
Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase.
Neoplasms
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Neoplasms
Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase.
Neoplasms
Role of Immune Microenvironment in Gastrointestinal Stromal Tumors.
Neoplasms
Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
Neoplasms
Role of indoleamine 2,3-dioxygenase in testicular immune-privilege.
Neoplasms
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Neoplasms
Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Neoplasms
Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.
Neoplasms
Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy.
Neoplasms
Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion.
Neoplasms
Serum from Asthmatic Mice Potentiates the Therapeutic Effects of Mesenchymal Stromal Cells in Experimental Allergic Asthma.
Neoplasms
Serum Tryptophan and Kynurenine Concentrations as Parameters for Indoleamine 2,3-Dioxygenase Activity in Patients With Endometrial, Ovarian, and Vulvar Cancer.
Neoplasms
Shaping the glioma immune microenvironment through tryptophan metabolism.
Neoplasms
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.
Neoplasms
Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy.
Neoplasms
Specific changes in faecal microbiota are associated with familial Mediterranean fever.
Neoplasms
Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2.
Neoplasms
Structural Basis of Selective Human Indoleamine-2,3-dioxygenase 1 (hIDO1) Inhibition.
Neoplasms
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.
Neoplasms
Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Neoplasms
Structure-activity Relationship of Indomethacin Derivatives as IDO1 Inhibitors.
Neoplasms
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.
Neoplasms
Studies on liver tryptophan pyrrolase of tumor bearing rats.
Neoplasms
Studies on tryptophan pyrrolase activity in tumour bearing mice.
Neoplasms
Substrate binding in human indoleamine 2,3-dioxygenase 1: A spectroscopic analysis.
Neoplasms
Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Neoplasms
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Neoplasms
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Neoplasms
Synthesis and evaluation of 6-[18F]fluoro-3-(pyridin-3-yl)-1H-indole as potential PET tracer for targeting tryptophan 2, 3-dioxygenase (TDO).
Neoplasms
Synthesis of 5-[(18)F]Fluoro-?-methyl Tryptophan: New Trp Based PET Agents.
Neoplasms
Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Neoplasms
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Neoplasms
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Neoplasms
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.
Neoplasms
Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Neoplasms
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Neoplasms
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Neoplasms
TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway.
Neoplasms
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.
Neoplasms
The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors.
Neoplasms
The complex roles of efferocytosis in cancer development, metastasis, and treatment.
Neoplasms
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
Neoplasms
The Correlation Between the Subsets of Tumor Infiltrating Memory T Cells and the Expression of Indoleamine 2,3-Dioxygenase in Gastric Cancer.
Neoplasms
The efficacy of indoximod upon stimulation with pro-inflammatory cytokines in triple-negative breast cancer cells.
Neoplasms
The equine alveolar macrophage: Functional and phenotypic comparisons with peritoneal macrophages.
Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Neoplasms
The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
Neoplasms
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.
Neoplasms
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.
Neoplasms
The immunoregulatory mechanisms of carcinoma for its survival and development.
Neoplasms
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
Neoplasms
The importance of cytokines and autoantibodies in depression.
Neoplasms
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.
Neoplasms
The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
Neoplasms
The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.
Neoplasms
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.
Neoplasms
The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Neoplasms
The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus.
Neoplasms
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Neoplasms
The Role of Congenital Cytomegalovirus Infection in Adverse Birth Outcomes: A Review of the Potential Mechanisms.
Neoplasms
The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Neoplasms
The role of IDO in brain tumor immunotherapy.
Neoplasms
The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Neoplasms
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.
Neoplasms
The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.
Neoplasms
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Neoplasms
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.
Neoplasms
The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment.
Neoplasms
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Neoplasms
Therapeutic cancer vaccines.
Neoplasms
Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells.
Neoplasms
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.
Neoplasms
Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells.
Neoplasms
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
Neoplasms
Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
Neoplasms
Tryptophan catabolites along the indoleamine 2,3-dioxygenase pathway as a biological link between depression and cancer.
Neoplasms
Tryptophan conjugated magnetic nanoparticles for targeting tumors overexpressing indoleamine 2,3 dioxygenase (IDO) and L-type amino acid transporter.
Neoplasms
Tryptophan degradation in transplanted tumor cells undergoing rejection.
Neoplasms
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
Neoplasms
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
Neoplasms
Tryptophan pyrrolase, kynureninase and kynurenine transaminase activities of human renal tumours.
Neoplasms
Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
Neoplasms
Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Neoplasms
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Neoplasms
Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy.
Neoplasms
Tumor-associated dendritic cells: molecular mechanisms to suppress antitumor immunity.
Neoplasms
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Neoplasms
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Neoplasms
Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells.
Neoplasms
Turn Off the IDO: Will Clinical Trials Be Successful?
Neoplasms
Type III TGF-? receptor downregulation generates an immunotolerant tumor microenvironment.
Neoplasms
Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism.
Neoplasms
Ultrasound-Driven Biomimetic Nanosystem Suppresses Tumor Growth and Metastasis through Sonodynamic Therapy, CO Therapy, and Indoleamine 2,3-Dioxygenase Inhibition.
Neoplasms
Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors.
Neoplasms
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells.
Neoplasms
Use of quantitative real-time PCR to determine the local inflammatory response in the intestinal mucosa and muscularis of horses undergoing small intestinal resection.
Neoplasms
Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model.
Neoplasms
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.
Neoplasms
[A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase]
Neoplasms
[Clinical Application of Immunosuppressive Factors in Cancer Diagnosis and Therapy].
Neoplasms
[Curcumin inhibiting the expression of indoleamine 2,3-dioxygenase induced by IFN-gamma in cancer cells]
Neoplasms
[Induction of indoleamine 2,3-dioxygenase after bacterial endotoxin treatment, viral infection or tumor transplantation, and its physiological significance]
Neoplasms
[Preparation of anti-human indoleamine 2,3-dioxygenase polyclonal antibody]
Neoplasms, Squamous Cell
Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients.
Neoplastic Cells, Circulating
Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
Nervous System Diseases
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2, 3-Dioxygenase with Therapeutic Activity in LLC tumor-bearing Mice.
Nervous System Diseases
IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4.
Nervous System Diseases
Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model.
Nervous System Diseases
The Effect of IDO on Neural Progenitor Cell Survival Under Oxygen Glucose Deprivation.
Neuralgia
Peripheral indoleamine 2,3-dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice.
Neuralgia
Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.
Neuroblastoma
Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Neurodegenerative Diseases
Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
Neurodegenerative Diseases
The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression.
Neurodegenerative Diseases
The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model.
Neurodegenerative Diseases
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.
Neuroendocrine Tumors
Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors.
Neuroinflammatory Diseases
Electroacupuncture Relieves LPS-Induced Depression-Like Behaviour in Rats Through IDO-Mediated Tryptophan-Degrading Pathway.
Neuroinflammatory Diseases
Fish oil ameliorates sickness behavior induced by lipopolysaccharide in aged mice through the modulation of kynurenine pathway.
Neuroinflammatory Diseases
Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy.
Neuroinflammatory Diseases
Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices.
Neuroinflammatory Diseases
Mastocytosis in adulthood and neuropsychiatric disorders.
Neuroinflammatory Diseases
Neuroinflammation and Depression: The Role of Indoleamine 2,3-dioxygenase (IDO) as a Molecular Pathway.
Non-alcoholic Fatty Liver Disease
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
Obesity
Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: Focus on brain indoleamine 2,3-dioxygenase activation.
Obesity
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Obesity
Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone.
Osteoarthritis
Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis.
Osteoarthritis
The role of indoleamine 2,3 dioxygenase 1 in the osteoarthritis.
Osteoarthritis
Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines.
Osteosarcoma
Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma.
Osteosarcoma
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma.
Ovarian Neoplasms
A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Ovarian Neoplasms
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Ovarian Neoplasms
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Ovarian Neoplasms
Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy".
Ovarian Neoplasms
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation.
Ovarian Neoplasms
Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
Ovarian Neoplasms
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Ovarian Neoplasms
Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ovarian Neoplasms
Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.
Ovarian Neoplasms
Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Ovarian Neoplasms
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Ovarian Neoplasms
Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy.
Ovarian Neoplasms
Ovarian Tumor Ascites CD14+ Cells Suppress Dendritic Cell-activated CD4+ T-cell Responses Through IL-10 Secretion and Indoleamine 2,3-Dioxygenase.
Ovarian Neoplasms
Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages.
Ovarian Neoplasms
Tryptophan catabolism in epithelial ovarian carcinoma.
Pancreatic Neoplasms
Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.
Pancreatic Neoplasms
Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.
Pancreatic Neoplasms
NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.
Pancreatic Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Pancreatitis
Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
Pancreatitis
Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade.
Pancreatitis
Indoleamine 2,3-dioxygenase is upregulated in the brain of rats with acute pancreatitis.
Papilloma
Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virus-Related Head and Neck Cancer.
Papillomavirus Infections
Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
Paracoccidioidomycosis
Regulatory T cells in paracoccidioidomycosis.
Paralysis
Poliovirus induces indoleamine-2,3-dioxygenase and quinolinic acid synthesis in macaque brain.
Paraparesis, Spastic
Central nervous system activation of the indoleamine-2,3-dioxygenase pathway in human T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.
Paratuberculosis
Indoleamine 2,3-Dioxygenase, Tryptophan Catabolism, and Mycobacterium avium subsp. paratuberculosis: a Model for Chronic Mycobacterial Infections.
Parkinson Disease
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Pellagra
Niacin metabolism and indoleamine 2,3-dioxygenase activation in malnourished patients with flaky paint dermatosis.
Pellagra
Tryptophan metabolism in patients with pellagra: problem of vitamin B 6 enzyme activity and feedback control of tryptophan pyrrolase enzyme.
Peritonitis
Blockade of indoleamine 2,3-dioxygenase reduces mortality from peritonitis and sepsis in mice by regulating functions of CD11b+ peritoneal cells.
Persistent Infection
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation.
Persistent Infection
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host.
Persistent Infection
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.
Placenta Accreta
Indoleamine 2,3-dioxygenase and trophoblast invasion in caesarean scar pregnancy: Implications for the aetiopathogenesis of placenta accreta spectrum.
Pneumonia
Is tryptophan catabolism increased under indoleamine 2,3 dioxygenase activity during chronic lung inflammation in pigs?
Pneumonia
Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia.
Pneumonia
Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines.
Pneumonia, Pneumococcal
Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia.
Pneumonia, Viral
Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases.
Porphyrias
Effects of acute carbamazepine administration on haem metabolism in rat liver.
Porphyrias
Glucose effect on tryptophan oxygenase and tyrosine aminotransferase induction after allylisopropylacetamide-induced porphyria in the rat.
Porphyrias
The activation and induction of tryptophan pyrrolase during experimental porphyria and by amino-triazole.
Porphyrias
Tryptophan pyrrolase, the regulatory free haem and hepatic porphyrias. Early depletion of haem by clinical and experimental exacerbators of porphyria.
Porphyrias
Tryptophan pyrrolase, tryptophan and tyrosine transaminase changes during allylisopropylacetamide-induced porphyria in the rat.
Porphyrias
[Behavior of hepatic tryptophan pyrrolase in porphyria induced with DDC in rats]
Porphyrias, Hepatic
Heme utilization by rat liver tryptophan pyrrolase as a screening test for exacerbation of hepatic porphyrias by drugs.
Porphyrias, Hepatic
Reduction of the C2 and C4 vinyl groups of Sn-protoporphyrin to form Sn-mesoporphyrin markedly enhances the ability of the metalloporphyrin to inhibit in vivo heme catabolism.
Porphyrias, Hepatic
Regulation of rat liver tryptophan pyrrolase by its cofactor haem: Experiments with haematin and 5-aminolaevulinate and comparison with the substrate and hormonal mechanisms.
Porphyrias, Hepatic
Tryptophan pyrrolase, the regulatory free haem and hepatic porphyrias. Early depletion of haem by clinical and experimental exacerbators of porphyria.
Pre-Eclampsia
Decreased tryptophan catabolism by placental indoleamine 2,3-dioxygenase in preeclampsia.
Pre-Eclampsia
Endothelial indoleamine 2,3-dioxygenase-1 regulates the placental vascular tone and is deficient in intrauterine growth restriction and pre-eclampsia.
Pre-Eclampsia
Genetic Variation in the Indoleamine 2,3-Dioxygenase Gene in Pre-eclampsia (Reply).
Pre-Eclampsia
Genetic Variation in the Indoleamine 2,3-Dioxygenase Gene in Pre-eclampsia.
Pre-Eclampsia
Indoleamine 2,3-Dioxygenase Gene in Pre-eclampsia.
Pre-Eclampsia
Mouse model for allogeneic immune reaction against fetus recapitulates human pre-eclampsia.
Pre-Eclampsia
Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypes.
Pre-Eclampsia
Reduced expression of indoleamine 2,3-dioxygenase participates in pathogenesis of preeclampsia via regulatory T cells.
Prostatic Neoplasms
Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
Prostatic Neoplasms
Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-? and TNF-? as Potential Biomarker of Prostate Cancer Progression.
Prostatic Neoplasms
High expression of indoleamine 2,3-dioxygenase gene in prostate cancer.
Prostatic Neoplasms
Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Prostatic Neoplasms
Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
Prostatic Neoplasms
Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer.
Prostatic Neoplasms
Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.
Prostatic Neoplasms
Small Molecules for Immunomodulation in Cancer.
Prostatic Neoplasms
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
Prostatic Neoplasms
The Prognostic Value of Indoleamine-2,3-Dioxygenase Gene Expression in Urine of Prostate Cancer Patients Undergoing Radical Prostatectomy as First Treatment of Choice.
Prostatic Neoplasms
Tumor-associated dendritic cells: molecular mechanisms to suppress antitumor immunity.
Proteinuria
RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus.
Psoriasis
Immune cells from Psoriasis patients are defective to induce Indoleamine 2,3-dioxygenase expression in response to inflammatory stimuli.
Psoriasis
Indoleamine 2,3-dioxygenase in psoriasis: a defective mechanism.
Psoriasis
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Psoriasis
The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients.
Pulmonary Disease, Chronic Obstructive
Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD.
Pulmonary Disease, Chronic Obstructive
Dysregulation of the Tryptophan Pathway Evidences Gender Differences in COPD.
Purpura, Thrombocytopenic, Idiopathic
Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia.
Rectal Neoplasms
Prognostic value of tumour-infiltrating CD8+?lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Renal Insufficiency
High activity of indoleamine 2,3-dioxygenase is associated with renal insufficiency in Puumala hantavirus induced nephropathia epidemica.
Renal Insufficiency, Chronic
Correlation of Indoleamine-2,3-Dioxygenase and Chronic Kidney Disease: A Pilot Study.
Renal Insufficiency, Chronic
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Renal Insufficiency, Chronic
RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus.
Reperfusion Injury
Indoleamine 2,3 dioxygenase (ido)expression in renal tubular epithelial cells contributes to renal ischemia reperfusion injury.
Reperfusion Injury
Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury.
Reperfusion Injury
Indoleamine 2,3-dioxygenase inhibition alters the non-coding RNA transcriptome following renal ischemia-reperfusion injury.
Reperfusion Injury
Nonviral gene delivery with indoleamine 2,3-dioxygenase targeting pulmonary endothelium protects against ischemia-reperfusion injury.
Reperfusion Injury
Role of indoleamine 2,3-dioxygenase in ischemia-reperfusion injury of renal tubular epithelial cells.
Reperfusion Injury
The protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition.
Reperfusion Injury
The role of indoleamine 2,3 dioxygenase in beneficial effects of stem cells in hind limb ischemia reperfusion injury.
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus Infection Reduces Kynurenic Acid Production and Reverses Th17/Treg Balance by Modulating Indoleamine 2,3-Dioxygenase (IDO) Molecules in Plasmacytoid Dendritic Cells.
Rheumatic Diseases
Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases.
Rhinitis, Allergic
Indoleamine 2,3-dioxygenase expression in patients with allergic rhinitis: a case-control study.
Rhinitis, Allergic, Seasonal
Specific Immunotherapy Normalizes Tryptophan Concentrations in Patients with Allergic Rhinitis.
Rickettsia Infections
Intralesional expression of mRNA of interferon- gamma , tumor necrosis factor- alpha , interleukin-10, nitric oxide synthase, indoleamine-2,3-dioxygenase, and RANTES is a major immune effector in Mediterranean spotted fever rickettsiosis.
Sarcoma
DNA regulatory elements for steroid hormones.
Sarcoma
IDO Targeting in Sarcoma: Biological and Clinical Implications.
Sarcoma, Ewing
Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.
Schistosomiasis mansoni
Effects of Schistosoma mansoni infection on induction of tryptophan oxygenase in mouse livers.
Scleroderma, Systemic
Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis.
Scleroderma, Systemic
The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis.
Scrub Typhus
Activation of Indoleamine 2,3-Dioxygenase in Patients with Scrub Typhus and Its Role in Growth Restriction of Orientia tsutsugamushi.
Seizures
Alzheimer's and seizures: interleukin-18, indoleamine 2,3-dioxygenase and quinolinic Acid.
Seizures
Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy.
Seizures
Prevention by cycloheximide of the audiogenic seizures and tryptophan metabolic disturbances of ethanol withdrawal in rats.
Seizures
Tryptophan pyrrolase activity in rats subjected to electric convulsions.
Sepsis
Blockade of indoleamine 2,3-dioxygenase reduces mortality from peritonitis and sepsis in mice by regulating functions of CD11b+ peritoneal cells.
Sepsis
Effect of 1-methyl-D-tryptophan and adoptive transfer of dendritic cells on polymicrobial sepsis induced by cecal content injection.
Sepsis
Endotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for Immunoparalysis.
Sepsis
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock.
Sepsis
Indoleamine 2,3-dioxygenase inhibitors: potential treatment for cancer, sepsis, and more.
Sepsis
Inhibition of indoleamine 2,3-dioxygenase 1/2 prevented cognitive impairment and energetic metabolism changes in the hippocampus of adult rats subjected to polymicrobial sepsis.
Sepsis
Mitochondria-Rich Fraction Isolated From Mesenchymal Stromal Cells Reduces Lung and Distal Organ Injury in Experimental Sepsis.
Sepsis
Regulation of vascular tone and blood pressure by singlet molecular oxygen in inflammation.
Sepsis
Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Shock, Septic
Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock.
Shock, Septic
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock.
Shock, Septic
Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Simian Acquired Immunodeficiency Syndrome
Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques.
Simian Acquired Immunodeficiency Syndrome
Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: relationship to clinical and viral status.
Skin Diseases
Effect of psoralen-induced photodermatitis on tryptophan metabolism in rats.
Skin Diseases
Immunotolerant indoleamine-2,3-dioxygenase increases in condyloma acuminata.
Skin Diseases
Niacin metabolism and indoleamine 2,3-dioxygenase activation in malnourished patients with flaky paint dermatosis.
Sleep Deprivation
Enzyme activity in sleep and sleep deprivation.
Small Cell Lung Carcinoma
NK cell-based therapeutics for lung cancer.
Squamous Cell Carcinoma of Head and Neck
Exosomes-carrying Epstein-Barr virus-encoded small RNA-1 induces indoleamine 2, 3-dioxygenase expression in tumor-infiltrating macrophages of oral squamous-cell carcinomas and suppresses T-cell activity by activating RIG-I/IL-6/TNF-? pathway.
Squamous Cell Carcinoma of Head and Neck
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways.
Squamous Cell Carcinoma of Head and Neck
Targeting the IDO-BCL2A1-Cytochrome c Pathway Promotes Apoptosis in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
Squamous Cell Carcinoma of Head and Neck
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.
Staphylococcal Infections
The induction of host tryptophan oxygenase by staphylococcal infection. 1.
Staphylococcal Infections
Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus infection by indoleamine 2,3-dioxygenase in rat aortic transplant model.
Starvation
Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.
Starvation
An insight into the early mechanisms of allergen-specific immunotherapy.
Starvation
Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma.
Starvation
Changes in rat liver weight and specific activity of hepatic tryptophan dioxygenase in different stages of fasting.
Starvation
Glycogen Synthase Kinase-3? (GSK-3?) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-?-induced Indoleamine 2,3-Dioxygenase Expression.
Starvation
Indoleamine 2,3-Dioxygenase (IDO) Regulates Th17/Treg Immunity in Experimental IgA Nephropathy.
Starvation
Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond.
Starvation
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle.
Starvation
Possible involvement of the enhanced tryptophan pyrrolase activity in the corticosterone- and starvation-induced increases in concentrations of nicotinamide-adenine dinucleotides (phosphates) in rat liver.
Starvation
Tryptophan Codon-Dependent Transcription in Chlamydia pneumoniae during Gamma Interferon-Mediated Tryptophan Limitation.
Starvation
Tryptophan pyrrolase gene expression in an alcohol preferring and non-preferring mouse strain.
Starvation
Tryptophan pyrrolase in haem regulation. The mechanisms of enhancement of rat liver 5-aminolaevulinate synthase activity by starvation and of the glucose effect on induction of the enzyme by 2-allyl-2-isopropylacetamide.
Stomach Neoplasms
Development of simultaneous analysis of tryptophan metabolites in serum and gastric juice - an investigation towards establishing a biomarker test for gastric cancer diagnosis.
Stomach Neoplasms
Immunoactivative role of indoleamine 2,3?dioxygenase in gastric cancer cells in vitro.
Stomach Neoplasms
The Correlation Between the Subsets of Tumor Infiltrating Memory T Cells and the Expression of Indoleamine 2,3-Dioxygenase in Gastric Cancer.
Stomach Neoplasms
The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
Stroke
The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines.
Thyroid Neoplasms
Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways.
Thyroid Neoplasms
[Indoleamine 2,3-Dioxygenase Activity during I131-Radioisotope Therapy for Metastatic Thyroid Cancer].
Thyroid Neoplasms
[Study of indoleamine 2,3-dioxygenase expression in patients of thyroid cancer].
Tics
BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
Tics
Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior.
Tourette Syndrome
Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior.
Toxoplasmosis
Heme oxygenase-1 activity is involved in the control of Toxoplasma gondii infection in the lung of BALB/c and C57BL/6 and in the small intestine of C57BL/6 mice.
Toxoplasmosis
Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following Toxoplasma gondii infection.
Toxoplasmosis
Indoleamine 2,3-Dioxygenase Activity During Acute Toxoplasmosis and the Suppressed T Cell Proliferation in Mice.
Toxoplasmosis
L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase.
Toxoplasmosis
Modulation of host HIF-1? activity and the tryptophan pathway contributes to the anti-
Triple Negative Breast Neoplasms
Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients.
Trophoblastic Neoplasms
Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches.
Tuberculosis
Evolutionary Views of Tuberculosis: Indoleamine 2,3-Dioxygenase Catalyzed Nicotinamide Synthesis Reflects Shifts in Macrophage Metabolism: Indoleamine 2,3-Dioxygenase Reflects Altered Macrophage Metabolism During Tuberculosis Pathogenesis.
Tuberculosis
Gene expression in HIV-1/Mycobacterium tuberculosis co-infected macrophages is dominated by M. tuberculosis.
Tuberculosis
Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients.
Tuberculosis, Multidrug-Resistant
Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients.
Tuberculosis, Pleural
Indoleamine 2,3-dioxygenase in the pathogenesis of tuberculous pleurisy.
Tuberculosis, Pulmonary
Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis.
Urinary Bladder Neoplasms
Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Uterine Cervical Neoplasms
Cell intrinsic & extrinsic factors in cervical carcinogenesis.
Uterine Cervical Neoplasms
Correlation between indoleamine 2,3 dioxygenase mRNA and CDKN2A/p16 mRNA: a combined strategy to cervical cancer diagnosis.
Uterine Cervical Neoplasms
Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation.
Uterine Cervical Neoplasms
Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
Uterine Cervical Neoplasms
Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.
Uterine Cervical Neoplasms
Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.
Uterine Cervical Neoplasms
Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival.
Uterine Cervical Neoplasms
MiR-218 produces anti-tumor effects on cervical cancer cells in vitro.
Uterine Cervical Neoplasms
Neem leaf glycoprotein overcomes indoleamine 2,3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical cancer stage IIIB patients.
Uterine Cervical Neoplasms
Systemic Changes of Tryptophan Catabolites via the Indoleamine-2,3-dioxygenase Pathway in Primary Cervical Cancer.
Vaccinia
Role of Indoleamine 2,3-Dioxygenase in Antiviral Activity of Interferon-gamma Against Vaccinia Virus.
Vasculitis
Mollaret meningitis may be caused by reactivation of latent cerebral toxoplasmosis.
Viremia
Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression.
Virus Diseases
Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.
Virus Diseases
Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection.
Virus Diseases
Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.
Virus Diseases
Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell-Derived Cells Suppresses Rhinovirus-Induced Neutrophilic Airway Inflammation by Regulating Th1- and Th17-Type Responses.
Virus Diseases
Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors.
Virus Diseases
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection.
Virus Diseases
Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.
Virus Diseases
Influenza A virus infection induces indoleamine 2,3-dioxygenase (IDO) expression and modulates subsequent inflammatory mediators in nasal epithelial cells.
Virus Diseases
Influenza virus induces expression of antioxidant genes in human epithelial cells.
Virus Diseases
Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection.
Virus Diseases
Interferons: Reprogramming the Metabolic Network against Viral Infection.
Virus Diseases
l-Kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species.
Virus Diseases
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients.
Virus Diseases
O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.
Virus Diseases
Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.
Virus Diseases
Respiratory Syncytial Virus Infection Reduces Kynurenic Acid Production and Reverses Th17/Treg Balance by Modulating Indoleamine 2,3-Dioxygenase (IDO) Molecules in Plasmacytoid Dendritic Cells.
Virus Diseases
Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.
Virus Diseases
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.
Virus Diseases
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.
Virus Diseases
Virus Infections Incite Pain Hypersensitivity by Inducing Indoleamine 2,3 Dioxygenase.
Virus Diseases
[Induction of indoleamine 2,3-dioxygenase after bacterial endotoxin treatment, viral infection or tumor transplantation, and its physiological significance]
Vitamin B 6 Deficiency
Oral contraceptives and depression: impact, prevalence and cause.
Vitiligo
Abnormal tryptophan pyrrolase and amino acids related to melanogenesis in vitiligo.
Vitiligo
Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: epidermal H2O2/ONOO--mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling.
Vitiligo
[Tryptophan metabolism in vitiligo]
Vulvar Neoplasms
Serum Tryptophan and Kynurenine Concentrations as Parameters for Indoleamine 2,3-Dioxygenase Activity in Patients With Endometrial, Ovarian, and Vulvar Cancer.
Warts
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0234
(-)-kurarinone
Homo sapiens
pH 6.5, 37°C
-
0.00317
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00123
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.03801
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.06604
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00064
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00578
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
Homo sapiens
22°C, pH 6.5
-
0.1783
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00187
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00285
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00012
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0314
(2S)-2'-methoxy kurarinone
Homo sapiens
pH 6.5, 37°C
-
0.5
(3-hydroxyphenyl)(phenyl)methanone
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000512
(3R,4S and 3S,4R)-3-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000361
(3R,4S and 3S,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00396
(3R,4S and 3S,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000183
(3R,4S and 3S,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000252
(3R,4S and 3S,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00345
(3R,4S and 3S,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000082
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.0015
(3S,4S and 3R,4R)-3,4-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
alpha-lapachone
0.0011
(3S,4S and 3R,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000976
(3S,4S and 3R,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000186
(3S,4S and 3R,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000055
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00109
(3S,4S and 3R,4R)-4-(benzyloxy)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00212
(3S,4S and 3R,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00013
(3S,4S)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00045
(4E,4'E)-4,4'-bis(isopropylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00052
(4E,4'E)-4,4'-bis(pentan-3-ylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00179
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0002
(E)-4-(isopropylimino)-2-methylnaphthalen-1(4H)-one
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.09
(R)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00034
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(1,4-dihydroxy-3-methylnaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
Homo sapiens
-
0.00088
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
Homo sapiens
-
0.06
(S)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0071
1,2-naphthoquinone
Homo sapiens
-
0.00099
1,4-naphtho-quinone
Homo sapiens
-
0.0293
1,6,6-trimethyl-10,11-dioxo-2-(thiophen-3-yl)-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
Homo sapiens
37°C, pH 6.5
-
0.0215
1,6,6-trimethyl-10,11-dioxo-2-phenyl-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
Homo sapiens
37°C, pH 6.5
-
0.00571
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl 1,3-thiazole-2-carboxylate
Homo sapiens
37°C, pH 6.5
-
0.00372
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl acetate
Homo sapiens
37°C, pH 6.5
-
0.00705
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclopropanecarboxylate
Homo sapiens
37°C, pH 6.5
-
0.0046
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl furan-3-carboxylate
Homo sapiens
37°C, pH 6.5
-
0.00274
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl hydroxyacetate
Homo sapiens
37°C, pH 6.5
-
0.00472
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
Homo sapiens
37°C, pH 6.5
-
0.00084
1,6,6-trimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
Homo sapiens
37°C, pH 6.5
-
0.05
1-(1,3-benzothiazol-2-ylsulfanyl)-N,N-dimethylmethanamine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000809
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.003163
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000767
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000602
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00064
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.01
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
above, pH 8.0, 37°C
0.000339
1-(4-bromophenyl)-2-[[5-(4-chlorophenyl)[1,3]thiazolo[2,3-c]-[1,2,4]triazol-3-yl]sulfanyl]ethanone
Homo sapiens
pH and temperature not specified in the publication
-
0.0000164
1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea
Homo sapiens
pH and temperature not specified in the publication
-
0.002587
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00177
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.001097
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.001593
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00037
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
Homo sapiens
37°C, pH 6.5
-
0.032
1-benzyl-5-phenyl-1H-imidazole
Homo sapiens
-
0.000081
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
0.4233
1-methyl-tryptophan
Homo sapiens
pH 6.5, 37°C
0.004612
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.01
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
above, pH 8.0, 37°C
0.00057
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00048
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00055
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
Homo sapiens
pH and temperature not specified in the publication
-
0.000936
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000982
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.002069
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000028
1-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-3-(4-methylphenyl)imidazolidin-2-one
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00495
2,2-dimethyl-1a,9b-dihydro-2H-benzo[g]oxireno[c]chromene-4,9-dione
Homo sapiens
pH and temperature not specified in the publication
0.000214
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
dehydro-alpha-lapachone
0.00434
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00495
2,2-dimethyl-3,4-epoxy-2H-naphtho[2,3-b]pyran-5,10-dione
Homo sapiens
-
0.00028
2,3-dichloro-1,4-naphthoquinone
Homo sapiens
-
0.0053
2-(1H-imidazol-4-yl)benzene-1,3-diol
Homo sapiens
-
0.025
2-(1H-imidazol-4-yl)benzenethiol
Homo sapiens
-
0.0048
2-(1H-imidazol-4-yl)phenol
Homo sapiens
-
0.035
2-(1H-pyrazol-3-yl)phenol
Homo sapiens
-
0.000922
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
Homo sapiens
pH 8.0, 37°C
0.25
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
above, pH 7.0, 22°C, IDO1
0.00087
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
Homo sapiens
pH and temperature not specified in the publication
-
0.00034
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
Homo sapiens
pH and temperature not specified in the publication
-
0.0002
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
Homo sapiens
pH and temperature not specified in the publication
-
0.00058
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
Homo sapiens
pH and temperature not specified in the publication
-
0.4
2-amino-3-hydroxy-N-(4-hydroxynaphthalen-1-yl)propanamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.105
2-amino-N-(4-hydroxynaphth-1-yl)acetamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.675
2-Hydroxy-1,4-naphthoquinone
Homo sapiens
-
0.05
2-mercaptobenzothiazole
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00072
2-methoxy-1,4-naphthoquinone
Homo sapiens
-
0.0011
2-methyl-1,4-naphthoquinone
Homo sapiens
-
0.0011
2-methylnaphthalene-1,4-dione
Homo sapiens
pH and temperature not specified in the publication
1
2-phenoxyaniline
Homo sapiens
IC50 above 1.0 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.01309
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.1371
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
Homo sapiens
22°C, pH 6.5
-
0.01833
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.04287
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.0000787
2-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00412
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.000022
3'-[[(2-chlorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00005
3'-[[(2-fluorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000042
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(2-methylpropyl)(propan-2-yl)amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000159
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(4aS,8aS)-octahydroquinolin-1(2H)-yl][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.68
3-(1H-1,2,3-triazol-5-yl)pyridine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.825
3-(1H-imidazol-4-yl)benzaldehyde
0.0076
3-(1H-imidazol-4-yl)benzenethiol
Homo sapiens
-
0.041
3-(1H-imidazol-4-yl)benzonitrile
Homo sapiens
-
0.365
3-(1H-imidazol-4-yl)phenol
Homo sapiens
-
0.00051
3-(2-aminoethyl)-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.000379
3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazole
Homo sapiens
pH and temperature not specified in the publication
-
0.0077
3-(4H-imidazol-4-yl)benzenethiol
Homo sapiens
-
0.00036
3-hydroxy-2,2-dimethyl-4-(morpholin-4-yl)-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00396
3-hydroxy-4-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.161
3-phenylpyridine
Homo sapiens
-
0.000977
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
Homo sapiens
pH 8.0, 37°C
0.001242
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
Homo sapiens
pH 8.0, 37°C
0.000065
3-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0015
3-[2-(cyclohexylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00226
3-[2-(diethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0005
3-[2-(dimethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00016
3-[2-(ethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00088
3-[2-(propylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00056
3-[2-(tert-butylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.004
3-[2-[(2-phenylethyl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00051
3-[2-[(propan-2-yl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.000141
3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.00016
4'-(2,3-dimethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0024
4'-(2-chlorophenoxy)-3'-([[4-(2-hydroxypropan-2-yl)phenyl]carbamoyl]amino)-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00083
4'-(2-chlorophenoxy)-3'-[[(4-chlorophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.006
4'-(2-chlorophenoxy)-3'-[[(4-cyanophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0021
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methoxyphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00084
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00054
4'-(2-ethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0006
4'-(2-tert-butylanilino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0045
4'-(2-tert-butylphenoxy)-2-fluoro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00007
4'-(2-tert-butylphenoxy)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0024
4'-(2-tert-butylphenoxy)-4-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00012
4'-(2-tert-butylphenoxy)-4-ethoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00035
4'-(2-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00025
4'-(2-tert-butylphenoxy)-5-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00069
4'-(3-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000504
4'-(cyclohexylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000045
4'-(dibutylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00028
4'-[(2,3-dihydro-1H-inden-4-yl)oxy]-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000013
4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000661
4'-[bis(2-methylpropyl)amino]-N-(methanesulfonyl)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000348
4'-[bis(cyclopropylmethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000014
4'-[cyclohexyl(methyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000023
4'-[cyclopentyl(ethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.005
4-(1H-1,2,3-triazol-5-yl)pyridine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
1.2
4-(1H-imidazol-4-yl)phenol
Homo sapiens
-
0.734
4-(2,6-dimethoxyphenyl)-1H-imidazole
Homo sapiens
-
0.003
4-(2-(diethylamino)ethylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.038
4-(2-(methylthio)phenyl)-1H-imidazole
Homo sapiens
-
0.179
4-(2-fluorophenyl)-1H-imidazole
0.0125
4-(2-hydroxyethoxy)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.073
4-(3-(methylthio)phenyl)-1H-imidazole
Homo sapiens
-
0.00033
4-(3-chlorophenyl)-imidazole
Homo sapiens
pH and temperature not specified in the publication
-
0.06
4-(3-fluorophenyl)-1H-imidazole
Homo sapiens
-
0.209
4-(4-(methylthio)phenyl)-1H-imidazole
Homo sapiens
-
0.0034
4-(4-bromophenyl)-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.0026
4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.123
4-(4-fluorophenyl)-1H-imidazole
Homo sapiens
-
0.0059
4-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.0025
4-(benzylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000055 - 0.00025
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
0.00013
4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.015
4-(cyclohexylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
1
4-(dimethylamino)naphthalen-1-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.016
4-(ethylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.025
4-(isobutylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0025
4-(isopropylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000043
4-(methanesulfonyl)-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.0125
4-(methylamino)naphthalen-1-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0035
4-(pent-3-ylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0045
4-(propylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.004
4-(tert-butylamino)naphthalen-1-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.422
4-(thiophen-2-yl)-1H-imidazole
0.03022
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
Homo sapiens
22°C, pH 6.5
-
0.003
4-amino-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000085
4-bromo-N'-(4-bromophenyl)benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.00011
4-chlorophenyl-1,2,3-triazol-4-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.000059
4-cyano-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.026
4-fluoro-2-(1H-pyrazol-3-yl)phenol
0.4
4-hydroxycarbazole
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0055
4-methoxy-1-naphthylamine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000062
4-methoxy-3'-[(phenylcarbamoyl)amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000049
4-methoxy-3'-[[(2-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0001
4-methoxy-3'-[[(3-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00033
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-(2-propylphenoxy)[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0001
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00034
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00005
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-methyl-3-[(prop-2-yn-1-yl)oxy]phenoxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
1
4-phenyl-1,3-thiazol-2-amine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.024
4-phenyl-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.05
4-phenyl-1,3-thiazole-2-thiol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00048 - 0.048
4-phenylimidazole
0.05718
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
Homo sapiens
22°C, pH 6.5
-
0.001928
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
Homo sapiens
pH 8.0, 37°C
0.002323
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
Homo sapiens
pH 8.0, 37°C
0.0002
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzamide
Homo sapiens
pH and temperature not specified in the publication
-
0.000199 - 0.000203
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
-
0.0000836
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.000061
4-[2-(4-bromophenyl)hydrazinesulfonyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.038
4-[2-(methylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH and temperature not specified in the publication
0.073
4-[3-(methylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH and temperature not specified in the publication
0.00564
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
Homo sapiens
22°C, pH 6.5
-
0.000256
5-(4-chlorophenyl)-3-[(2-methylpropyl)sulfanyl][1,3]thiazolo-[2,3-c][1,2,4]triazole
Homo sapiens
pH and temperature not specified in the publication
-
0.04
5-(ethylamino)quinolin-8-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.015
5-(isopropylamino)quinolin-8-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.003
5-amino-8-hydroxyquinoline
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.05
5-chloro-1,3-benzothiazole-2(3H)-thione
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.001
5-hydroxy-1,4-naphthoquinone
Homo sapiens
-
0.06
5-phenyl-1H-1,2,3-triazole
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0088
5-[(2E)-2-[(4-bromophenyl)methylidene]hydrazinyl]-1-(naphthalen-1-yl)tetrazolidine
Homo sapiens
pH 6.5, 37°C
-
0.00945
6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00109
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.03207
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.203
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
Homo sapiens
22°C, pH 6.5
-
0.05155
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.1049
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.0555
6-bromo-N-[[(1S,2R)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00029
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.01736
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.05645
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.01375
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00474
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00019
6-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00019
6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00213
6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.0031
7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
Homo sapiens
37°C, pH 6.5
-
0.00552
7-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00302
7-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.01309
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00078
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00046
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
Homo sapiens
pH and temperature not specified in the publication
-
0.000534
8-fluorotryptanthrin
Homo sapiens
pH and temperature not specified in the publication
-
0.002 - 0.00205
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
0.000933
8-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.2
9-fluorenone
Homo sapiens
IC50 above 0.2 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00283
9-hydroxy-1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
Homo sapiens
37°C, pH 6.5
-
0.000121
9-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
alpha-caryopterone
1
9-hydroxyfluorene
Homo sapiens
IC50 above 1.0 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00292
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
0.000017
antisense oligonucleotide A06007H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000036
antisense oligonucleotide A06008H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000011
antisense oligonucleotide A06030H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000049
antisense oligonucleotide A06043H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000205
antisense oligonucleotide A06044H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000078
antisense oligonucleotide A06045H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000368
antisense oligonucleotide A07006H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000842
antisense oligonucleotide A07058H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
1
benzophenone
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.07
Dichlorophene
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00001 - 0.00009
epacadostat
-
0.00019
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
Homo sapiens
pH and temperature not specified in the publication
-
0.00747
ethyl 1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl (2E)-but-2-enedioate
Homo sapiens
37°C, pH 6.5
-
0.0077
galanal
Homo sapiens
pH 6.5, 37°C, recombinant His-tagged enzyme
0.00088
gamma-glutamyl-S-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cysteinylglycine
Homo sapiens
pH and temperature not specified in the publication
0.000097
INCB024360
Homo sapiens
pH and temperature not specified in the publication
-
0.0077
kushenol E
Homo sapiens
pH 6.5, 37°C
0.0254
kushenol F
Homo sapiens
pH 6.5, 37°C
-
0.00064
menadione
Homo sapiens
in PBS buffer (pH 7.4), at 37°C
0.00143
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
Homo sapiens
pH and temperature not specified in the publication
-
0.0012
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
Homo sapiens
pH and temperature not specified in the publication
-
0.00046
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
Homo sapiens
pH and temperature not specified in the publication
-
0.000247
methyl 2-methyl-5,10-dioxo-5,10-dihydro-2H-benzo[g]chromene-2-carboxylate
Homo sapiens
-
0.000121
methyl 3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoate
Homo sapiens
pH and temperature not specified in the publication
0.00366
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
Homo sapiens
22°C, pH 6.5
-
0.0216
methyl thiohydantoin-Trp
Homo sapiens
pH 7.0, 22°C, IDO1
0.000059
N'-(3-methylphenyl)-4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.000176
N'-(4-bromophenyl)-4-cyanobenzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.001431
N'-(4-bromophenyl)-4-methoxybenzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.000172
N'-(4-bromophenyl)benzenesulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.000405
N'-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N-methyl-N-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
1
N,N-dimethyl-1-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]methanamine
Homo sapiens
IC50 above 1.0 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.003
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
pH 7.0, 22°C, IDO1
0.000056
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
22°C, pH 6.5
-
0.000076
N-(4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-yl)-1,1,1-trifluoromethanesulfonamide
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0029
N-(4-bromophenyl)-N'-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.044
N-(4-hydroxy-1-naphthyl)ethane-1,2-diaminium chloride
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.005
N-(4-hydroxy-1-naphthyl)propane-1,3-diaminium chloride
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.2
N-(4-hydroxynaphthalen-1-yl)pyrrolidine-2-carboxamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.001605
N-(4-[2-[4-(trifluoromethyl)phenyl]hydrazinesulfonyl]phenyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00161
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
Homo sapiens
22°C, pH 6.5
-
0.25
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
above, pH 7.0, 22°C, IDO1
0.4
N-phenyl-p-phenylenediamine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0238
N-[(1,3-benzothiazol-2-yl)sulfanyl]-2-nitrobenzene-1-sulfonamide
Homo sapiens
pH 6.5, 37°C
-
0.1127
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00077
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]-2,2-dimethylpropanamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00136
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00208
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00351
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzenesulfonamide
Homo sapiens
pH and temperature not specified in the publication
-
0.000071
N-[4-(2-phenylhydrazinesulfonyl)phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.001
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(2-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00057
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(3-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0018
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methoxyphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00079
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0015
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-phenylurea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0026
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(difluoromethoxy)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.004
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000608
N-[4-[2-(2,4-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000247
N-[4-[2-(3,4-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000352
N-[4-[2-(3,5-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.001746
N-[4-[2-(3,5-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000128
N-[4-[2-(3-bromo-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000255
N-[4-[2-(3-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00011
N-[4-[2-(3-chloro-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000122
N-[4-[2-(3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00008
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]benzoyl]glycine
Homo sapiens
pH and temperature not specified in the publication
0.000049
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000205
N-[4-[2-(4-bromo-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000058
N-[4-[2-(4-bromo-3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00023
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-chlorophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000146
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-cyanophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.00048
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-fluorophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000461
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methoxyphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000536
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000184
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-chlorophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000607
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methoxyphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000703
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000157
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-butylurea
Homo sapiens
pH and temperature not specified in the publication
-
0.000161
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-cyclohexylurea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000726
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[3-(1H-tetrazol-5-yl)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000207
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[4-(1H-tetrazol-5-yl)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication
-
0.00013
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000132
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]butanamide
Homo sapiens
pH and temperature not specified in the publication
0.000194
N-[4-[2-(4-chloro-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000155
N-[4-[2-(4-chlorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.005667
N-[4-[2-(4-cyanophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000079
N-[4-[2-(4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000254
N-[4-[2-(4-methoxyphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000051
N-[4-[2-(4-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.002475
N-[4-[2-(4-sulfamoylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000005 - 0.000097
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
-
0.000004
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0007
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00142
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00008
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-4-oxobutanamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00069
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00073
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00063
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00081
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00045
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.0015
naphthalene-1,4-diol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00099
naphthalene-1,4-dione
Homo sapiens
pH and temperature not specified in the publication
0.0235
noranhydroicaritin
Homo sapiens
pH 6.5, 37°C
0.05
primaquine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.001202
propan-2-yl 4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoate
Homo sapiens
pH and temperature not specified in the publication
-
0.75
quinolin-8-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0193
sophoraflavanone B
Homo sapiens
pH 6.5, 37°C
0.00902
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
Homo sapiens
22°C, pH 6.5
-
0.00294
tert-butyl [2-(4,7-dioxo-5-phenyl-4,7-dihydro-1H-indol-3-yl)ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.0019
tert-butyl [2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.00209
tert-butyl [2-[5-(2-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.00238
tert-butyl [2-[5-(2-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.001
vitamin K3
Homo sapiens
-
0.000125
[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenoxy]acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.0035
(2,4-dichlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0012
(2-chlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0001
(3,4-dichlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0032
(4-chlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
(4-chlorophenyl)methanol
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0018
(4-fluorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0014
(4-methoxyphenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0013
(4-methylphenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-(4-chlorobenzyl)urea
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-(4-chlorophenyl)methanamine
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-(4-chlorophenyl)thiourea
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-[2-(4-chlorophenyl)ethyl]thiourea
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0044 - 0.013
15-deoxy-DELTA12,14-prostaglandin
2.57
1H-benzotriazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.0004
2,4-dichlorobenzyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
2-(2-chlorophenyl)ethyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
2-(3-chlorophenyl)ethyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
2-(4-chlorophenyl)ethanamine
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.057
2-(4-chlorophenyl)ethyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.25
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
above, pH 7.0, 22°C, IDO2
0.01
2-chlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.017
3,4-dichlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.708
3-(1H-1,2,3-triazol-5-yl)pyridine
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.0046
3-chlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-(phenylcarbonyl)benzyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-(propan-2-yl)benzyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0026
4-(trifluoromethyl)benzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0021
4-amino-N'-hydroxy-N-(3-isopropylphenyl)-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0044
4-amino-N'-hydroxy-N-(3-methoxyphenyl)-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.00055
4-amino-N'-hydroxy-N-(3-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0032
4-amino-N'-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0065
4-amino-N-(2-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.000059
4-amino-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.000073
4-amino-N-(3-bromophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.000067
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0014
4-amino-N-(3-chlorophenyl)-1,2,5-oxadiazole-3-carbohydrazonamide
Homo sapiens
-
-
0.000086
4-amino-N-(3-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.00043
4-amino-N-(3-ethylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0005
4-amino-N-(3-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.025
4-amino-N-(3-tert-butylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.006
4-amino-N-(4-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
1.028
4-bromo-5-(4-methylphenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.0013
4-bromobenzyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-chlorobenzenesulfonic acid
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0019
4-chlorobenzenethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0022
4-chlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.021
4-chlorobenzyl N,N'-dimethylcarbamimidothioate - 1-chlorotetraoxidane (1:1)
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.019
4-cyanobenzyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.016
4-ethylbenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.013
4-fluorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
1.371
4-iodo-5-phenyl-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.052
4-methoxybenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.03
4-methylbenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.533
4-nitro-5-(4-nitrophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.011
4-nitrobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-tert-butylbenzyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-[(carbamimidoylsulfanyl)methyl]benzoic acid hydrochloride
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.148
5-(2-bromophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.086
5-(2-chlorophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
1.028
5-(2-methoxyphenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
1.256
5-(4-bromophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.817
5-(4-chlorophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.58
5-(4-fluorophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
6
5-(4-methoxyphenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.143
5-phenyl-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.061
benzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0093
Berberine
Homo sapiens
-
pH and temperature not specified in the publication
2
ethyl 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.1
methyl 4-[(carbamimidoylsulfanyl)methyl]benzenesulfinate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
methyl N-(4-chlorophenyl)carbamimidothioate hydroiodide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
methyl N-[2-(4-chlorophenyl)ethyl]carbamimidothioate hydroiodide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0826
methyl thiohydantoin-Trp
Homo sapiens
pH 7.0, 22°C, IDO2
0.25
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
above, pH 7.0, 22°C, IDO2
0.25
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
above, pH 7.0, 22°C, IDO2
0.0017
phenylmethanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.006 - 0.0095
prostaglandin (19R)-hydroxy-PGE2
0.0067 - 0.03
prostaglandin 13,14-dihydro-15-oxo-PGE2
0.0068 - 0.009
prostaglandin 15-oxo-PGE2
0.0076 - 0.0231
prostaglandin 15-oxo-PGF2alpha
0.0074 - 0.0112
prostaglandin 20-hydroxy PGE2
0.0046 - 0.0071
prostaglandin DELTA12-PGJ2
0.0049 - 0.0078
prostaglandin PGA2
0.0041 - 0.0074
prostaglandin PGD2
0.0047 - 0.0057
prostaglandin PGD2 ethanolamide
0.01 - 0.0221
prostaglandin PGE2
0.0046 - 0.0063
prostaglandin PGE2 ethanolamide
0.0071 - 0.0074
prostaglandin PGF2beta
0.0092 - 0.0112
prostaglandin PGG2
0.0072 - 0.0096
prostaglandin PGH2
0.0042 - 0.0067
prostaglandin PGJ2
0.1
sodium 4-chlorobenzenesulfinate
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
additional information
additional information
Homo sapiens
review article sumarizing data of many inhibitors of indoleamine 2,3-dioxygenase
-
0.825
3-(1H-imidazol-4-yl)benzaldehyde
Homo sapiens
-
0.825
3-(1H-imidazol-4-yl)benzaldehyde
Homo sapiens
pH and temperature not specified in the publication
0.179
4-(2-fluorophenyl)-1H-imidazole
Homo sapiens
-
0.179
4-(2-fluorophenyl)-1H-imidazole
Homo sapiens
pH and temperature not specified in the publication
0.000055
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00025
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.422
4-(thiophen-2-yl)-1H-imidazole
Homo sapiens
-
0.422
4-(thiophen-2-yl)-1H-imidazole
Homo sapiens
pH and temperature not specified in the publication
0.026
4-fluoro-2-(1H-pyrazol-3-yl)phenol
Homo sapiens
-
0.026
4-fluoro-2-(1H-pyrazol-3-yl)phenol
Homo sapiens
pH and temperature not specified in the publication
0.00048
4-phenylimidazole
Homo sapiens
pH and temperature not specified in the publication
0.048
4-phenylimidazole
Homo sapiens
-
0.000199
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
-
0.000203
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
-
0.002
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00205
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00292
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00292
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00001
epacadostat
Homo sapiens
pH and temperature not specified in the publication
-
0.000086
epacadostat
Homo sapiens
pH 6.5, 37°C
-
0.00009
epacadostat
Homo sapiens
pH and temperature not specified in the publication
-
0.000005
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000097
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0044
15-deoxy-DELTA12,14-prostaglandin
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.013
15-deoxy-DELTA12,14-prostaglandin
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.006
prostaglandin (19R)-hydroxy-PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0095
prostaglandin (19R)-hydroxy-PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0067
prostaglandin 13,14-dihydro-15-oxo-PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.03
prostaglandin 13,14-dihydro-15-oxo-PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0068
prostaglandin 15-oxo-PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.009
prostaglandin 15-oxo-PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0076
prostaglandin 15-oxo-PGF2alpha
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0231
prostaglandin 15-oxo-PGF2alpha
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0074
prostaglandin 20-hydroxy PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0112
prostaglandin 20-hydroxy PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0046
prostaglandin DELTA12-PGJ2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0071
prostaglandin DELTA12-PGJ2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0049
prostaglandin PGA2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0078
prostaglandin PGA2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0041
prostaglandin PGD2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0074
prostaglandin PGD2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0047
prostaglandin PGD2 ethanolamide
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0057
prostaglandin PGD2 ethanolamide
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.01
prostaglandin PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0221
prostaglandin PGE2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0046
prostaglandin PGE2 ethanolamide
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0063
prostaglandin PGE2 ethanolamide
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0071
prostaglandin PGF2beta
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0074
prostaglandin PGF2beta
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0092
prostaglandin PGG2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0112
prostaglandin PGG2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0072
prostaglandin PGH2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
0.0096
prostaglandin PGH2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0042
prostaglandin PGJ2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human monocytes
0.0067
prostaglandin PGJ2
Homo sapiens
-
pH not specified in the publication, 37°C, inhibition of human THP-1 cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Badawy, A.A.
Central role of tryptophan pyrrolase in haem metabolism
Biochem. Soc. Trans.
7
575-583
1979
Bos taurus, Cavia porcellus, Gallus gallus, Oryctolagus cuniculus, Felis catus, Frog, Meriones unguiculatus, Cricetinae, Ovis aries, Homo sapiens, Meleagris gallopavo, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Littlejohn, T.K.; Takikawa, O.; Skylas, D.; Jamie, J.F.; Walker, M.J.; Truscott, R.J.W.
Expression and purification of recombinant human indoleamine 2,3-dioxygenase
Protein Expr. Purif.
19
22-29
2000
Homo sapiens
brenda
Thomas, S.R.; Mohr, D.; Stocker, R.
Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes
J. Biol. Chem.
269
14457-14464
1994
Homo sapiens
brenda
Hissong, B.D.; Byrne, G.I.; Padilla, M.L.; Carlin, J.M.
Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1
Cell. Immunol.
160
264-269
1995
Homo sapiens
brenda
Takikawa, O.; Littlejohn, T.K.; Truscott, R.J.W.
Indoleamine 2,3-dioxygenase in the human lens, the first enzyme in the synthesis of UV filters
Exp. Eye Res.
72
271-277
2001
Homo sapiens
brenda
Kudo, Y.; Boyd, C.A.R.; Sargent, I.L.; Redman, C.W.G.
Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation
J. Physiol.
535
207-215
2001
Homo sapiens
brenda
Kudo, Y.; Boyd, C.A.R.
Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection
Biochim. Biophys. Acta
1500
119-124
2000
Homo sapiens
brenda
Musso, T.; Gusella, G.L.; Brooks, A.; Longo, D.L.; Varesio, L.
Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes
Blood
83
1408-1411
1994
Homo sapiens
brenda
Terentis, A.C.; Thomas, S.R.; Takikawa, O.; Littlejohn, T.K.; Truscott, R.J.W.; Armstrong, R.S.; Yeh, S.R.; Stocker, R.
The heme environment of recombinant human indoleamine 2,3-dioxygenase: Structural properties and substrate-ligand interactions
J. Biol. Chem.
277
15788-15794
2002
Homo sapiens
brenda
Terness, P.; Bauer, T.M.; Rose, L.; Dufter, C.; Watzlik, A.; Simon, H.; Opelz, G.
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites
J. Exp. Med.
196
447-457
2002
Homo sapiens
brenda
Comings, D.E.; Muhleman, D.; Dietz, G.; Sherman, M.; Forest, G.L.
Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat
Genomics
29
390-396
1995
Homo sapiens (P48775)
brenda
Kadoya, A.; Tone, S.; Mareda, H.; Minatogawa, Y.; Kido, R.
Gene structure of human indoleamine 2,3-dioxygenase
Biochem. Biophys. Res. Commun.
189
530-536
1992
Homo sapiens (P14902), Homo sapiens
brenda
Dai, W.; Gupta, S.L.
Molecular cloning, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA
Biochem. Biophys. Res. Commun.
168
1-8
1990
Homo sapiens (P14902), Homo sapiens
brenda
Tone, S.; Takikawa, O.; Habara-Ohkubo, A.; Kadoxa, A.; Yoshida, R.; Kido, R.
Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA
Nucleic Acids Res.
18
367
1990
Homo sapiens (P14902), Homo sapiens
brenda
Kwidzinski, E.; Bunse, J.; Kovac, A.D.; Ullrich, O.; Zipp, F.; Nitsch, R.; Bechmann, I.
IDO (indolamine 2,3-dioxygenase) expression and function in the CNS
Adv. Exp. Med. Biol.
527
113-118
2003
Homo sapiens
brenda
Takikawa, O.; Truscott, R.J.; Fukao, M.; Miwa, S.
Age-related nuclear cataract and indoleamine 2,3-dioxygenase-initiated tryptophan metabolism in the human lens
Adv. Exp. Med. Biol.
527
277-285
2003
Homo sapiens
brenda
Sedlmayr, P.; Semlitsch, M.; Gebru, G.; Karpf, E.; Reich, O.; Tang, T.; Wintersteiger, R.; Takikawa, O.; Dohr, G.
Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix
Adv. Exp. Med. Biol.
527
91-95
2003
Homo sapiens
brenda
Ferry, G.; Ubeaud, C.; Lambert, P.H.; Bertin, S.; Coge, F.; Chomarat, P.; Delagrange, P.; Serkiz, B.; Bouchet, J.P.; Truscott, R.J.W.; Boutin, J.A.
Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase
Biochem. J.
388
205-215
2005
Homo sapiens (P48775)
brenda
Kudo, Y.; Hara, T.; Katsuki, T.; Toyofuku, A.; Katsura, Y.; Takikawa, O.; Fujii, T.; Ohama, K.
Mechanisms regulating the expression of indoleamine 2,3-dioxygenase during decidualization of human endometrium
Hum. Reprod.
19
1222-1230
2004
Homo sapiens
brenda
Littlejohn, T.K.; Takikawa, O.; Jamie, J.F.; Walker, M.J.; Truscott, R.J.W.
Production of truncated enzymically active human indoleamine 2,3-dioxygenase using site-directed mutagenesis
Int. Congr. Ser.
1233
157-160
2002
Homo sapiens
-
brenda
Littlejohn, T.K.; Takikawa, O.; Truscott, R.J.W.; Walker, M.J.
Asp274 and His346 are essential for heme binding and catalytic function of human indolamine 2,3-dioxygenase
J. Biol. Chem.
278
29525-29531
2003
Homo sapiens
brenda
von Bubnoff, D.; Bausinger, H.; Matz, H.; Koch, S.; Hacker, G.; Takikawa, O.; Bieber, T.; Hanau, D.; de la Salle, H.
Human epidermal langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
J. Invest. Dermatol.
123
298-304
2004
Homo sapiens
brenda
Kudo, Y.; Boyd, C.A.; Spyropoulou, I.; Redman, C.W.; Takikawa, O.; Katsuki, T.; Hara, T.; Ohama, K.; Sargent, I.L.
Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta
J. Reprod. Immunol.
61
87-98
2004
Homo sapiens
brenda
Ligam, P.; Manuelpillai, U.; Wallace, E.M.; Walker, D.
Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy
Placenta
26
498-504
2005
Homo sapiens
brenda
Austin, C.J.; Mizdrak, J.; Matin, A.; Sirijovski, N.; Kosim-Satyaputra, P.; Willows, R.D.; Roberts, T.H.; Truscott, R.J.; Polekhina, G.; Parker, M.W.; Jamie, J.F.
Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase
Protein Expr. Purif.
37
392-398
2004
Homo sapiens
brenda
Kai, S.; Goto, S.; Tahara, K.; Sasaki, A.; Tone, S.; Kitano, S.
Indolamine 2,3-dioxygenase is necessary for cytolytic activity of natural killer cells
Scand. J. Immunol.
59
177-182
2004
Homo sapiens
brenda
Watanabe, Y.; Fujiwara, M.; Yoshida, R.; Hayaishi, O.
Stereospecificity of hepatic L-tryptophan 2,3-dioxygenase
Biochem. J.
189
393-405
1980
Bos taurus, Capra hircus, Oryctolagus cuniculus, Homo sapiens, Macaca fuscata fuscata, Mus musculus, Pseudomonas fluorescens, Rattus norvegicus, Sus scrofa
brenda
Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W.; Dilloo, D.
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation
Blood
103
4619-4621
2004
Homo sapiens
brenda
Daubener, W.; Spors, B.; Hucke, C.; Adam, R.; Stins, M.; Kim, K.S.; Schroten, H.
Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase
Infect. Immun.
69
6527-6531
2001
Homo sapiens
brenda
Southan, M.D.; Truscott, R.J.W.; Jamie, J.F.; Pelosi, L.; Walker, M.J.; Maeda, H.; Iwamoto, Y.; Tone, S.
Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase
Med. Chem. Res.
6
343-352
1996
Homo sapiens
-
brenda
Sedlmayr, P.; Blaschitz, A.; Wintersteiger, R.; Semlitsch, M.; Hammer, A.; MacKenzie, C.R.; Walcher, W.; Reich, O.; Takikawa, O.; Dohr, G.
Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta
Mol. Hum. Reprod.
8
385-391
2002
Homo sapiens
brenda
Yasui, H.; Takai, K.; Yoshida, R.; Hayaishi, O.
Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients
Proc. Natl. Acad. Sci. USA
83
6622-6626
1986
Homo sapiens
brenda
Thomas, S.R.; Stocker, R.
Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway
Redox Rep.
4
199-220
1999
Oryctolagus cuniculus, Homo sapiens, Mus musculus
brenda
Oda, S.; Sugimoto, H.; Yoshida, T.; Shiro, Y.
Crystallization and preliminary crystallographic studies of human indoleamine 2,3-dioxygenase
Acta Crystallogr. Sect. F
62
221-223
2006
Homo sapiens
brenda
Beutelspacher, S.C.; Tan, P.H.; McClure, M.O.; Larkin, D.F.; Lechler, R.I.; George, A.J.
Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses
Am. J. Transplant.
6
1320-1330
2006
Homo sapiens
brenda
Takikawa, O.
Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism
Biochem. Biophys. Res. Commun.
338
12-19
2005
Oryctolagus cuniculus, Homo sapiens
brenda
Papadopoulou, N.D.; Mewies, M.; McLean, K.J.; Seward, H.E.; Svistunenko, D.A.; Munro, A.W.; Raven, E.L.
Redox and spectroscopic properties of human indoleamine 2,3-dioxygenase and a His303Ala variant: implications for catalysis
Biochemistry
44
14318-14328
2005
Homo sapiens
brenda
Samelson-Jones, B.J.; Yeh, S.R.
Interactions between nitric oxide and indoleamine 2,3-dioxygenase
Biochemistry
45
8527-8538
2006
Homo sapiens (P14902), Homo sapiens
brenda
Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R.J.; Mauk, A.G.; Roberge, M.
Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast
Biotechnol. J.
1
282-288
2006
Homo sapiens
brenda
von Bergwelt-Baildon, M.S.; Popov, A.; Saric, T.; Chemnitz, J.; Classen, S.; Stoffel, M.S.; Fiore, F.; Roth, U.; Beyer, M.; Debey, S.; Wickenhauser, C.; Hanisch, F.G.; Schultze, J.L.
CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition
Blood
108
228-237
2006
Homo sapiens
brenda
Brastianos, H.C.; Vottero, E.; Patrick, B.O.; Van Soest, R.; Matainaho, T.; Mauk, A.G.; Andersen, R.J.
Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua
J. Am. Chem. Soc.
128
16046-16047
2006
Homo sapiens
brenda
Pereira, A.; Vottero, E.; Roberge, M.; Mauk, A.G.; Andersen, R.J.
Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata
J. Nat. Prod.
69
1496-1499
2006
Homo sapiens
brenda
Sugimoto, H.; Oda, S.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y.
Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase
Proc. Natl. Acad. Sci. USA
103
2611-2616
2006
Homo sapiens
brenda
Austin, C.J.; Astelbauer, F.; Kosim-Satyaputra, P.; Ball, H.J.; Willows, R.D.; Jamie, J.F.; Hunt, N.H.
Mouse and human indoleamine 2,3-dioxygenase display some distinct biochemical and structural properties
Amino Acids
36
99-106
2009
Mus musculus, Homo sapiens (P14902), Homo sapiens
brenda
Basran, J.; Rafice, S.A.; Chauhan, N.; Efimov, I.; Cheesman, M.R.; Ghamsari, L.; Raven, E.L.
A kinetic, spectroscopic, and redox study of human tryptophan 2,3-dioxygenase
Biochemistry
47
4752-4760
2008
Homo sapiens, Homo sapiens (P48775)
brenda
Chauhan, N.; Basran, J.; Efimov, I.; Svistunenko, D.A.; Seward, H.E.; Moody, P.C.; Raven, E.L.
The role of serine 167 in human indoleamine 2,3-dioxygenase: a comparison with tryptophan 2,3-dioxygenase
Biochemistry
47
4761-4769
2008
Homo sapiens, Xanthomonas campestris
brenda
Macchiarulo, A.; Nuti, R.; Bellocchi, D.; Camaioni, E.; Pellicciari, R.
Molecular docking and spatial coarse graining simulations as tools to investigate substrate recognition, enhancer binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO)
Biochim. Biophys. Acta
1774
1058-1068
2007
Homo sapiens (P14902)
brenda
Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C.
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Cancer Res.
67
7082-7087
2007
Homo sapiens
brenda
Pertovaara, M.; Raitala, A.; Juonala, M.; Lehtimaeki, T.; Huhtala, H.; Oja, S.S.; Jokinen, E.; Viikari, J.S.; Raitakari, O.T.; Hurme, M.
Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the cardiovascular risk in young Finns study
Clin. Exp. Immunol.
148
106-111
2007
Homo sapiens
brenda
Torres, M.I.; Lopez-Casado, M.A.; Lorite, P.; Rios, A.
Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease
Clin. Exp. Immunol.
148
419-424
2007
Homo sapiens
brenda
Werner, E.R.; Werner-Felmayer, G.
Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide
Curr. Drug Metab.
8
201-203
2007
Homo sapiens
brenda
Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H.
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Gene
396
203-213
2007
Homo sapiens (Q6ZQW0), Homo sapiens, Mus musculus (Q8R0V5), Mus musculus
brenda
King, N.J.; Thomas, S.R.
Molecules in focus: indoleamine 2,3-dioxygenase
Int. J. Biochem. Cell Biol.
39
2167-2172
2007
Homo sapiens, Mus musculus
brenda
Batabyal, D.; Yeh, S.R.
Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase
J. Am. Chem. Soc.
129
15690-15701
2007
Homo sapiens
brenda
Chung, L.W.; Li, X.; Sugimoto, H.; Shiro, Y.; Morokuma, K.
Density functional theory study on a missing piece in understanding of heme chemistry: the reaction mechanism for indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase
J. Am. Chem. Soc.
130
12299-12309
2008
Homo sapiens
brenda
Thomas, S.R.; Terentis, A.C.; Cai, H.; Takikawa, O.; Levina, A.; Lay, P.A.; Freewan, M.; Stocker, R.
Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide
J. Biol. Chem.
282
23778-23787
2007
Homo sapiens
brenda
Yuasa, H.J.; Takubo, M.; Takahashi, A.; Hasegawa, T.; Noma, H.; Suzuki, T.
Evolution of vertebrate indoleamine 2,3-dioxygenases
J. Mol. Evol.
65
705-714
2007
Homo sapiens (P14902), Mus musculus (P28776), Mus musculus, Rattus norvegicus (Q9ERD9)
brenda
Larrea, E.; Riezu-Boj, J.I.; Gil-Guerrero, L.; Casares, N.; Aldabe, R.; Sarobe, P.; Civeira, M.P.; Heeney, J.L.; Rollier, C.; Verstrepen, B.; Wakita, T.; Borras-Cuesta, F.; Lasarte, J.J.; Prieto, J.
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection
J. Virol.
81
3662-3666
2007
Homo sapiens, Pan troglodytes
brenda
Corm, S.; Berthon, C.; Imbenotte, M.; Biggio, V.; Lhermitte, M.; Dupont, C.; Briche, I.; Quesnel, B.
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients sera by HPLC and is inducible by IFN-gamma
Leuk. Res.
33
490-494
2009
Homo sapiens
brenda
Macchiarulo, A.; Camaioni, E.; Nuti, R.; Pellicciari, R.
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
Amino Acids
37
219-229
2009
Mus musculus, Homo sapiens (P14902)
brenda
Rafice, S.A.; Chauhan, N.; Efimov, I.; Basran, J.; Raven, E.L.
Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase
Biochem. Soc. Trans.
37
408-412
2009
Saccharomyces cerevisiae, Oryctolagus cuniculus, Drosophila melanogaster, Homo sapiens, Mus musculus, Cupriavidus metallidurans, Xanthomonas campestris
brenda
Nakashima, H.; Uto, Y.; Nakata, E.; Nagasawa, H.; Ikkyu, K.; Hiraoka, N.; Nakashima, K.; Sasaki, Y.; Sugimoto, H.; Shiro, Y.; Hashimoto, T.; Okamoto, Y.; Asakawa, Y.; Hori, H.
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors
Bioorg. Med. Chem.
16
8661-8669
2008
Homo sapiens
brenda
Curti, A.; Trabanelli, S.; Salvestrini, V.; Baccarani, M.; Lemoli, R.M.
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood
113
2394-2401
2009
Homo sapiens
brenda
Clarke, G.; Fitzgerald, P.; Cryan, J.F.; Cassidy, E.M.; Quigley, E.M.; Dinan, T.G.
Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort
BMC Gastroenterol.
9
6
2009
Homo sapiens
brenda
Qian, F.; Villella, J.; Wallace, P.K.; Mhawech-Fauceglia, P.; Tario, J.D.; Andrews, C.; Matsuzaki, J.; Valmori, D.; Ayyoub, M.; Frederick, P.J.; Beck, A.; Liao, J.; Cheney, R.; Moysich, K.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K.
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer
Cancer Res.
69
5498-5504
2009
Homo sapiens
brenda
Schmidt, S.K.; Mueller, A.; Heseler, K.; Woite, C.; Spekker, K.; MacKenzie, C.R.; Daeubener, W.
Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase
Eur. J. Immunol.
39
2755-2764
2009
Homo sapiens
brenda
Quan, J.; Tan, P.H.; MacDonald, A.; Friend, P.J.
Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges
Expert. Opin. Biol. Ther.
8
1705-1719
2008
Homo sapiens
brenda
Spekker, K.; Czesla, M.; Ince, V.; Heseler, K.; Schmidt, S.K.; Schares, G.; Daeubener, W.
Indoleamine 2,3-dioxygenase is involved in defense against Neospora caninum in human and bovine cells
Infect. Immun.
77
4496-4501
2009
Bos taurus, Homo sapiens
brenda
Cherayil, B.J.
Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation
Inflamm. Bowel Dis.
15
1391-1396
2009
Homo sapiens, Mus musculus
brenda
Lu, C.; Lin, Y.; Yeh, S.R.
Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase
J. Am. Chem. Soc.
131
12866-12867
2009
Homo sapiens
brenda
Fukumura, E.; Sugimoto, H.; Misumi, Y.; Ogura, T.; Shiro, Y.
Cooperative binding of L-trp to human tryptophan 2,3-dioxygenase: resonance Raman spectroscopic analysis
J. Biochem.
145
505-515
2009
Homo sapiens
brenda
Nickel, E.; Nienhaus, K.; Lu, C.; Yeh, S.R.; Nienhaus, G.U.
Ligand and substrate migration in human indoleamine 2,3-dioxygenase
J. Biol. Chem.
284
31548-31554
2009
Homo sapiens
brenda
Mueller, A.; Heseler, K.; Schmidt, S.K.; Spekker, K.; Mackenzie, C.R.; Daeubener, W.
The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects
J. Cell. Mol. Med.
13
1125-1135
2008
Homo sapiens
brenda
Becerra, A.; Warke, R.V.; Xhaja, K.; Evans, B.; Evans, J.; Martin, K.; de Bosch, N.; Rothman, A.L.; Bosch, I.
Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function
J. Gen. Virol.
90
810-817
2009
Homo sapiens
brenda
Chen, W.; Liang, X.; Peterson, A.J.; Munn, D.H.; Blazar, B.R.
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation
J. Immunol.
181
5396-5404
2008
Homo sapiens
brenda
Kumar, S.; Malachowski, W.P.; DuHadaway, J.B.; LaLonde, J.M.; Carroll, P.J.; Jaller, D.; Metz, R.; Prendergast, G.C.; Muller, A.J.
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors
J. Med. Chem.
51
1706-1718
2008
Homo sapiens (P14902)
brenda
Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J.M.; DuHadaway, J.B.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J.
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase
J. Med. Chem.
51
4968-4977
2008
Homo sapiens (P14902)
brenda
Yue, E.W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K.J.; Hansbury, M.J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T.C.; Koblish, H.K.; Fridman, J.S.; Metcalf, B.; Scherle, P.A.; Combs, A.P.
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model
J. Med. Chem.
52
7364-7367
2009
Homo sapiens
brenda
Mailankot, M.; Staniszewska, M.M.; Butler, H.; Caprara, M.H.; Howell, S.; Wang, B.; Doller, C.; Reneker, L.W.; Nagaraj, R.H.
Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens
Lab. Invest.
89
498-512
2009
Homo sapiens
brenda
Hoshi, M.; Ito, H.; Fujigaki, H.; Takemura, M.; Takahashi, T.; Tomita, E.; Ohyama, M.; Tanaka, R.; Saito, K.; Seishima, M.
Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity
Leuk. Res.
33
39-45
2009
Homo sapiens
brenda
Zelante, T.; Fallarino, F.; Bistoni, F.; Puccetti, P.; Romani, L.
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host
Microbes Infect.
11
133-141
2009
Homo sapiens
brenda
Schefold, J.C.; Zeden, J.P.; Fotopoulou, C.; von Haehling, S.; Pschowski, R.; Hasper, D.; Volk, H.D.; Schuett, C.; Reinke, P.
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms
Nephrol. Dial. Transplant.
24
1901-1908
2009
Homo sapiens
brenda
Arefayene, M.; Philips, S.; Cao, D.; Mamidipalli, S.; Desta, Z.; Flockhart, D.A.; Wilkes, D.S.; Skaar, T.C.
Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity
Pharmacogenet. Genomics
19
464-476
2009
Homo sapiens (P14902), Homo sapiens
brenda
Huttunen, R.; Syrjaenen, J.; Aittoniemi, J.; Oja, S.S.; Raitala, A.; Laine, J.; Pertovaara, M.; Vuento, R.; Huhtala, H.; Hurme, M.
High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients
Shock
33
149-154
2010
Homo sapiens
brenda
Liu, J.; Lu, G.; Tang, F.; Liu, Y.; Cui, G.
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas
Virchows Arch.
455
441-448
2009
Homo sapiens
brenda
Nishizawa, H.; Kato, T.; Ota, S.; Nishiyama, S.; Pryor-Koishi, K.; Suzuki, M.; Tsutsumi, M.; Inagaki, H.; Kurahashi, H.; Udagawa, Y.
Genetic variation in the indoleamine 2,3-dioxygenase gene in pre-eclampsia
Am. J. Reprod. Immunol.
64
68-76
2010
Homo sapiens
brenda
Yanagisawa, S.; Sugimoto, H.; Shiro, Y.; Ogura, T.
A specific interaction of L-tryptophan with CO of CO-bound indoleamine 2,3-dioxygenase identified by resonance Raman spectroscopy
Biochemistry
49
10081-10088
2010
Homo sapiens
brenda
Pearson, J.T.; Siu, S.; Meininger, D.P.; Wienkers, L.C.; Rock, D.A.
In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b5 and methylene blue
Biochemistry
49
2647-2656
2010
Homo sapiens (P14902)
brenda
Lu, C.; Lin, Y.; Yeh, S.R.
Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase
Biochemistry
49
5028-5034
2010
Homo sapiens
brenda
Matsuno, K.; Takai, K.; Isaka, Y.; Unno, Y.; Sato, M.; Takikawa, O.; Asai, A.
S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase
Bioorg. Med. Chem. Lett.
20
5126-5129
2010
Homo sapiens
brenda
Soerensen, R.B.; Hadrup, S.R.; Svane, I.M.; Hjortso, M.C.; Thor Straten, P.; Andersen, M.H.
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Blood
117
2200-2210
2011
Homo sapiens
brenda
Juergens, B.; Fuchs, D.; Reichenbach, J.; Heitger, A.
Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease
Clin. Immunol.
137
1-4
2010
Homo sapiens
brenda
John, S.; Thangapandian, S.; Sakkiah, S.; Lee, K.W.
Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies
Eur. J. Med. Chem.
45
4004-4012
2010
Homo sapiens (P14902)
brenda
Di Pucchio, T.; Danese, S.; De Cristofaro, R.; Rutella, S.
Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds
Expert Opin. Ther. Pat.
20
229-250
2010
Homo sapiens
brenda
Matteoli, G.; Mazzini, E.; Iliev, I.D.; Mileti, E.; Fallarino, F.; Puccetti, P.; Chieppa, M.; Rescigno, M.
Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction
Gut
59
595-604
2010
Homo sapiens, Mus musculus
brenda
Mailankot, M.; Nagaraj, R.H.
Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine
Int. J. Biochem. Cell Biol.
42
1446-1454
2010
Homo sapiens
brenda
Jiang, G.M.; He, Y.W.; Fang, R.; Zhang, G.; Zeng, J.; Yi, Y.M.; Zhang, S.; Bu, X.Z.; Cai, S.H.; Du, J.
Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels
Int. J. Biochem. Cell Biol.
42
1840-1846
2010
Homo sapiens
brenda
Yu, C.J.; Zheng, M.F.; Kuang, C.X.; Huang, W.D.; Yang, Q.
Oren-gedoku-to and its constituents with therapeutic potential in Alzheimers disease inhibit indoleamine 2, 3-dioxygenase activity in vitro
J. Alzheimers Dis.
22
257-266
2010
Homo sapiens
brenda
Davydov, R.M.; Chauhan, N.; Thackray, S.J.; Anderson, J.L.; Papadopoulou, N.D.; Mowat, C.G.; Chapman, S.K.; Raven, E.L.; Hoffman, B.M.
Probing the ternary complexes of indoleamine and tryptophan 2,3-dioxygenases by cryoreduction EPR and ENDOR spectroscopy
J. Am. Chem. Soc.
132
5494-5500
2010
Homo sapiens, Shewanella oneidensis, Xanthomonas campestris
brenda
Tattevin, P.; Monnier, D.; Tribut, O.; Dulong, J.; Bescher, N.; Mourcin, F.; Uhel, F.; Le Tulzo, Y.; Tarte, K.
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock
J. Infect. Dis.
201
956-966
2010
Homo sapiens
brenda
Roehrig, U.F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.; Colau, D.; Cerundolo, V.; Simpson, A.J.; Vogel, P.; Van den Eynde, B.J.; Zoete, V.; Michielin, O.
Rational design of indoleamine 2,3-dioxygenase inhibitors
J. Med. Chem.
53
1172-1189
2010
Homo sapiens (P14902)
brenda
Avril, T.; Saikali, S.; Vauleon, E.; Jary, A.; Hamlat, A.; De Tayrac, M.; Mosser, J.; Quillien, V.
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions
J. Neuroimmunol.
225
22-33
2010
Homo sapiens
brenda
Samikkannu, T.; Rao, K.V.; Gandhi, N.; Saxena, S.K.; Nair, M.P.
Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS
J. NeuroVirol.
16
255-263
2010
Homo sapiens
brenda
Mao, R.; Zhang, J.; Jiang, D.; Cai, D.; Levy, J.M.; Cuconati, A.; Block, T.M.; Guo, J.T.; Guo, H.
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells
J. Virol.
85
1048-1057
2011
Homo sapiens (P14902), Homo sapiens
brenda
Mouratidis, P.X.; George, A.J.
Transfection of indoleamine 2,3 dioxygenase in primary endothelial cells
Methods Mol. Biol.
616
149-159
2010
Homo sapiens
brenda
Orabona, C.; Grohmann, U.
Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond
Methods Mol. Biol.
677
269-280
2011
Homo sapiens
brenda
Capece, L.; Arrar, M.; Roitberg, A.E.; Yeh, S.R.; Marti, M.A.; Estrin, D.A.
Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase
Proteins
78
2961-2972
2010
Homo sapiens (P14902), Homo sapiens, Xanthomonas campestris (Q8PDA8)
brenda
Bonda, D.J.; Mailankot, M.; Stone, J.G.; Garrett, M.R.; Staniszewska, M.; Castellani, R.J.; Siedlak, S.L.; Zhu, X.; Lee, H.G.; Perry, G.; Nagaraj, R.H.; Smith, M.A.
Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimers disease
Redox Rep.
15
161-168
2010
Homo sapiens
brenda
Fatokun, A.A.; Hunt, N.H.; Ball, H.J.
Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease
Amino Acids
45
1319-1329
2013
Homo sapiens, Mus musculus
brenda
Capece, L.; Lewis-Ballester, A.; Marti, M.A.; Estrin, D.A.; Yeh, S.R.
Molecular basis for the substrate stereoselectivity in tryptophan dioxygenase
Biochemistry
50
10910-10918
2011
Homo sapiens, Xanthomonas campestris
brenda
Meininger, D.; Zalameda, L.; Liu, Y.; Stepan, L.P.; Borges, L.; McCarter, J.D.; Sutherland, C.L.
Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
Biochim. Biophys. Acta
1814
1947-1954
2011
Homo sapiens (F5H5G0), Homo sapiens (P14902), Homo sapiens
brenda
Huang, Q.; Zheng, M.; Yang, S.; Kuang, C.; Yu, C.; Yang, Q.
Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors
Eur. J. Med. Chem.
46
5680-5687
2011
Homo sapiens
brenda
Eleftheriadis, T.; Pissas, G.; Karioti, A.; Antoniadi, G.; Liakopoulos, V.; Dafopoulou, K.; Pournaras, S.; Koukoulis, G.; Stefanidis, I.
The indoleamine 2,3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes
Immunol. Invest.
41
507-520
2012
Homo sapiens
brenda
Freewan, M.; Rees, M.D.; Plaza, T.S.; Glaros, E.; Lim, Y.J.; Wang, X.S.; Yeung, A.W.; Witting, P.K.; Terentis, A.C.; Thomas, S.R.
Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions: implications for the inhibition of dioxygenase activity by hydrogen peroxide
J. Biol. Chem.
288
1548-1567
2013
Homo sapiens
brenda
Wu, W.; Nicolazzo, J.A.; Wen, L.; Chung, R.; Stankovic, R.; Bao, S.S.; Lim, C.K.; Brew, B.J.; Cullen, K.M.; Guillemin, G.J.
Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimers disease brain
PLoS ONE
8
e59749
2013
Homo sapiens, Mus musculus
brenda
Kuo, H.H.; Mauk, A.G.
Indole peroxygenase activity of indoleamine 2,3-dioxygenase
Proc. Natl. Acad. Sci. USA
109
13966-13971
2012
Homo sapiens
brenda
Pantouris, G.; Serys, M.; Yuasa, H.J.; Ball, H.J.; Mowat, C.G.
Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
Amino Acids
46
2155-2163
2014
Homo sapiens (P14902), Homo sapiens (Q6ZQW0), Homo sapiens
brenda
Kolawole, A.O.; Hixon, B.P.; Dameron, L.S.; Chrisman, I.M.; Smirnov, V.V.
Catalytic activity of human indoleamine 2,3-dioxygenase (hIDO1) at low oxygen
Arch. Biochem. Biophys.
570
47-57
2015
Homo sapiens (P14902), Homo sapiens
brenda
Alvarez, L.; Lewis-Ballester, A.; Roitberg, A.; Estrin, D.A.; Yeh, S.R.; Marti, M.A.; Capece, L.
Structural study of a flexible active site loop in human indoleamine 2,3-dioxygenase and its functional implications
Biochemistry
55
2785-2793
2016
Homo sapiens (P14902), Homo sapiens
brenda
Nienhaus, K.; Nickel, E.; Nienhaus, G.U.
Substrate binding in human indoleamine 2,3-dioxygenase 1 a spectroscopic analysis
Biochim. Biophys. Acta
1865
453-463
2017
Homo sapiens (P14902), Homo sapiens
brenda
Cheng, M.F.; Hung, M.S.; Song, J.S.; Lin, S.Y.; Liao, F.Y.; Wu, M.H.; Hsiao, W.; Hsieh, C.L.; Wu, J.S.; Chao, Y.S.; Shih, C.; Wu, S.Y.; Ueng, S.H.
Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors
Bioorg. Med. Chem. Lett.
24
3403-3406
2014
Homo sapiens (P14902)
brenda
Tomek, P.; Palmer, B.D.; Flanagan, J.U.; Sun, C.; Raven, E.L.; Ching, L.M.
Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) probing the active site-inhibitor interactions
Eur. J. Med. Chem.
126
983-996
2017
Homo sapiens (P14902)
brenda
Eleftheriadis, T.; Pissas, G.; Antoniadi, G.; Liakopoulos, V.; Stefanidis, I.
Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells
Immunology
146
292-300
2015
Homo sapiens (P14902), Homo sapiens
brenda
Eleftheriadis, T.; Pissas, G.; Sounidaki, M.; Tsogka, K.; Antoniadis, N.; Antoniadi, G.; Liakopoulos, V.; Stefanidis, I.
Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferaseI activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells
Int. J. Mol. Med.
38
1605-1613
2016
Homo sapiens (P14902), Homo sapiens
brenda
Booth, E.S.; Basran, J.; Lee, M.; Handa, S.; Raven, E.L.
Substrate oxidation by indoleamine 2,3-dioxygenase evidence for a common reaction mechanism
J. Biol. Chem.
290
30924-30930
2015
Homo sapiens (P14902)
brenda
Yuasa, H.J.; Ball, H.J.
Efficient tryptophan-catabolizing activity is consistently conserved through evolution of TDO enzymes, but not IDO enzymes
J. Exp. Zool. B
324
128-140
2015
Strongylocentrotus purpuratus, Xenopus laevis (A2BD60), Nematostella vectensis (A7SDW8), Monosiga brevicollis (A9UVU0), Danio rerio (B0V1K8), Branchiostoma floridae (C3Y9Y8), Homo sapiens (P14902), Mus musculus (P28776), Mus musculus (Q8R0V5), Haliotis diversicolor (Q6F3I3)
brenda
Wu, J.S.; Lin, S.Y.; Liao, F.Y.; Hsiao, W.C.; Lee, L.C.; Peng, Y.H.; Hsieh, C.L.; Wu, M.H.; Song, J.S.; Yueh, A.; Chen, C.H.; Yeh, S.H.; Liu, C.Y.; Lin, S.Y.; Yeh, T.K.; Hsu, J.T.; Shih, C.; Ueng, S.H.; Hung, M.S.; Wu, S.Y.
Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening
J. Med. Chem.
58
7807-7819
2015
Homo sapiens (P14902)
brenda
Li, R.; Li, H.; Sun, Q.; Liu, L.; Zhang, C.; Ren, X.
Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway
Mol. Immunol.
81
102-107
2017
Homo sapiens (P14902), Homo sapiens
brenda
Gonzalez Esquivel, D.; Ramirez-Ortega, D.; Pineda, B.; Castro, N.; Rios, C.; Perez de la Cruz, V.
Kynurenine pathway metabolites and enzymes involved in redox reactions
Neuropharmacology
112
331-345
2017
Homo sapiens (P14902), Homo sapiens (Q6ZQW0), Mus musculus (P28776)
brenda
Yamamoto, R.; Yamamoto, Y.; Imai, S.; Fukutomi, R.; Ozawa, Y.; Abe, M.; Matuo, Y.; Saito, K.
Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity galanal is a novel, competitive inhibitor of the enzyme
PLoS ONE
9
e88789
2014
Homo sapiens (P14902), Homo sapiens
brenda
Costabile, M.; Bassal, N.K.; Gerber, J.P.; Hughes, B.P.
Inhibition of indoleamine 2,3-dioxygenase activity by fatty acids and prostaglandins A structure function analysis
Prostaglandins Leukot. Essent. Fatty Acids
122
7-15
2017
Homo sapiens
brenda
Lin, S.Y.; Yeh, T.K.; Song, J.S.; Hung, M.S.; Cheng, M.F.; Liao, F.Y.; Li, A.S.; Cheng, S.Y.; Lin, L.M.; Chiu, C.H.; Wu, M.H.; Lin, Y.J.; Hsiao, W.; Sun, M.; Wang, Y.H.; Huang, C.H.; Tang, Y.C.; Chang, H.H.; Huang, Z.T.; Chao, Y.S.; Shih, C.; Pan, S.L.; Wu, S.Y.; Kuo, C.C.; Ueng, S.H.
4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy
Bioorg. Chem.
77
600-607
2018
Homo sapiens (P14902)
brenda
Balti, M.; Plas, A.; Meinguet, C.; Haufroid, M.; Themans, Q.; Efrit, M.L.; Wouters, J.; Lanners, S.
Synthesis of 4- and 5-arylthiazolinethiones as inhibitors of indoleamine 2,3-dioxygenase
Bioorg. Med. Chem. Lett.
27
3607-3610
2017
Homo sapiens (P14902), Homo sapiens
brenda
Markwalder, J.A.; Seitz, S.P.; Blat, Y.; Elkin, L.; Hunt, J.T.; Pabalan, J.G.; Jure-Kunkel, M.N.; Vite, G.D.; Covello, K.
Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors
Bioorg. Med. Chem. Lett.
27
582-585
2017
Homo sapiens (P14902)
brenda
Griglio, A.; Torre, E.; Serafini, M.; Bianchi, A.; Schmid, R.; Coda Zabetta, G.; Massarotti, A.; Sorba, G.; Pirali, T.; Fallarini, S.
A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors Synthesis, biological investigation and docking studies
Bioorg. Med. Chem. Lett.
28
651-657
2018
Homo sapiens (P14902)
brenda
Williams, D.K.; Markwalder, J.A.; Balog, A.J.; Chen, B.; Chen, L.; Donnell, J.; Haque, L.; Hart, A.C.; Mandal, S.K.; Nation, A.; Shan, W.; Vite, G.D.; Covello, K.; Hunt, J.T.; Jure-Kunkel, M.N.; Seitz, S.P.
Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Bioorg. Med. Chem. Lett.
28
732-736
2018
Homo sapiens (P14902), Homo sapiens
brenda
Kong, K.M.; Zhang, J.W.; Liu, B.Z.; Meng, G.R.; Zhang, Q.
Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Bioorg. Med. Chem. Lett.
30
126901
2020
Homo sapiens (P14902)
brenda
Li, Y.; Zhang, S.; Wang, R.; Cui, M.; Liu, W.; Yang, Q.; Kuang, C.
Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase
Bioorg. Med. Chem. Lett.
30
127159
2020
Homo sapiens (P14902)
brenda
Yanagisawa, S.; Kayama, K.; Hara, M.; Sugimoto, H.; Shiro, Y.; Ogura, T.
UV Resonance Raman characterization of a substrate bound to human indoleamine 2,3-dioxygenase 1
Biophys. J.
117
706-716
2019
Homo sapiens (P14902)
brenda
Klar, R.; Michel, S.; Schell, M.; Hinterwimmer, L.; Zippelius, A.; Jaschinski, F.
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
Cancer Immunol. Immunother.
69
57-67
2020
Homo sapiens (P14902), Homo sapiens
brenda
Xu, H.; Song, Y.; Yang, Q.
A novel high throughput virtual screening protocol to discover new indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Chem. Pharm. Bull.
65
714-717
2017
Homo sapiens (P14902)
brenda
Kwon, M.; Ko, S.K.; Jang, M.; Kim, G.H.; Ryoo, I.J.; Son, S.; Ryu, H.W.; Oh, S.R.; Lee, W.K.; Kim, B.Y.; Jang, J.H.; Ahn, J.S.
Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity
J. Enzyme Inhib. Med. Chem.
34
1481-1488
2019
Homo sapiens (P14902)
brenda
Roehrig, U.F.; Reynaud, A.; Majjigapu, S.R.; Vogel, P.; Pojer, F.; Zoete, V.
Inhibition mechanisms of indoleamine 2,3-dioxygenase 1 (IDO1)
J. Med. Chem.
62
8784-8795
2019
Homo sapiens (P14902)
brenda
Peng, Y.H.; Liao, F.Y.; Tseng, C.T.; Kuppusamy, R.; Li, A.S.; Chen, C.H.; Fan, Y.S.; Wang, S.Y.; Wu, M.H.; Hsueh, C.C.; Chang, J.Y.; Lee, L.C.; Shih, C.; Shia, K.S.; Yeh, T.K.; Hung, M.S.; Kuo, C.C.; Song, J.S.; Wu, S.Y.; Ueng, S.H.
Unique sulfur-aromatic interactions contribute to the binding of potent imidazothiazole indoleamine 2,3-dioxygenase inhibitors
J. Med. Chem.
63
1642-1659
2020
Homo sapiens (P14902)
brenda
Ning, X.L.; Li, Y.Z.; Huo, C.; Deng, J.; Gao, C.; Zhu, K.R.; Wang, M.; Wu, Y.X.; Yu, J.L.; Ren, Y.L.; Luo, Z.Y.; Li, G.; Chen, Y.; Wang, S.Y.; Peng, C.; Yang, L.L.; Wang, Z.Y.; Wu, Y.; Qian, S.; Li, G.B.
X-ray structure-guided discovery of a potent, orally bioavailable, dual human indoleamine/tryptophan 2,3-dioxygenase (hIDO/hTDO) inhibitor that shows activity in a mouse model of Parkinsons disease
J. Med. Chem.
64
8303-8332
2021
Homo sapiens (P14902), Homo sapiens
brenda
Bando, H.; Lee, Y.; Sakaguchi, N.; Pradipta, A.; Ma, J.S.; Tanaka, S.; Cai, Y.; Liu, J.; Shen, J.; Nishikawa, Y.; Sasai, M.; Yamamoto, M.
Inducible nitric oxide synthase is a key host factor for Toxoplasma GRA15-dependent disruption of the gamma interferon-induced antiparasitic human response
mBio
9
e01738-18
2018
Homo sapiens (P14902)
brenda
Zhao, H.; Sun, P.; Guo, W.; Wang, Y.; Zhang, A.; Meng, L.; Ding, C.
Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product
Molecules
24
1059
2019
Homo sapiens (P14902)
brenda
Sari, S.; Tomek, P.; Leung, E.; Reynisson, J.
Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening
Molecules
24
4346
2019
Homo sapiens (P14902)
brenda
Dolsak, A.; Gobec, S.; Sova, M.
Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets
Pharmacol. Ther.
221
107746
2021
Homo sapiens (P14902), Homo sapiens (Q6ZQW0)
brenda